System for analyzing and controlling dosing information of consumable media

Abstract

A vaporizing article includes a vaporizer drive circuit; one or more memories configured to store a percentage of at least one component in an inhaled medium, one or more compensation values ​​for at least one compensation category of the at least one component, and instructions; and a control circuit including a processor coupled to the one or more memories configured to execute the instructions, the instructions configured to cause the processor to: receive a dosage target for a component; determine whether to perform compensation for an inhaled medium dosage to ensure that the dosage target is achieved; when compensation is to be performed, determine an appropriately compensated inhaled medium dosage based on the associated compensation value for the component; and control the vaporizer drive circuit to dispense the compensated dosage of the inhaled medium.

Description

Background Art

[0001] Personal vaporizers are a popular alternative to traditional tobacco-based cigarettes, which must be burned to generate smoke for inhalation. Personal vaporizers can provide vapor for inhalation, but do not produce certain combustion byproducts that may be harmful to human health. A personal vaporizer is an electronic inhaler that evaporates or atomizes a liquid solution into an aerosol (which can then be delivered to the user). A typical vaporizer has two main parts—1) a housing that houses the battery and control electronics, and 2) a liquid storage component. The housing that houses the battery typically includes a rechargeable lithium-ion (Li-ion) battery and an activation sensor. The liquid storage component typically includes a liquid solution, an atomizer, and a mouthpiece, but the atomizer may reside in the housing in certain configurations. The atomizer typically includes a heating element that vaporizes the liquid solution. Some advanced vaporizers also have the ability to communicate with a computer network, typically via a wireless connection to a mobile phone. Summary of the invention

[0002] According to one aspect of the present disclosure, a vaporizing article includes a vaporizer drive circuit; one or more memories configured to store a percentage of at least one component in an inhaled medium, one or more compensation values ​​for at least one compensation category of the at least one component, and instructions; and a control circuit including a processor coupled to the one or more memories configured to execute the instructions, the instructions being configured to cause the processor to: receive a dosage target of a component; determine whether to perform compensation for the inhaled medium dosage to ensure that the dosage target is achieved; when compensation is to be performed, determine an appropriately compensated inhaled medium dosage based on the associated compensation value of the component; and control the vaporizer drive circuit to dispense the compensated dosage of the inhaled medium.

[0003] By considering the following detailed description, accompanying drawings and claims, additional features, advantages and embodiments of the present disclosure may be set forth or become apparent. In addition, it should be understood that the foregoing summary of the present disclosure and the following detailed description are exemplary and intended to provide further explanation without limiting the scope of the present disclosure claimed. BRIEF DESCRIPTION OF THE DRAWINGS

[0004] The accompanying drawings, which are included to provide a further understanding of the present disclosure, are incorporated into and constitute a part of this specification, illustrate embodiments of the present disclosure, and together with the detailed description, are used to explain the principles of the present disclosure. No attempt is made to show the structural details of the present disclosure in more detail, except for a basic understanding of the present disclosure and the various ways in which the present disclosure can be practiced. In the drawings:

[0005] Figure 1aAn example of an evaporator article constructed according to one aspect of the present disclosure is shown.

[0006] Figure 1b Another exemplary form of an evaporator article constructed in accordance with one aspect of the present disclosure is shown.

[0007] Figure 1c Another exemplary user interface of an evaporator article constructed according to one aspect of the present disclosure is shown.

[0008] Figure 2 Shows Figure 1a An interior view of the evaporator article is shown.

[0009] Figure 3 Another example of an evaporator article constructed according to one aspect of the present disclosure is shown.

[0010] Figure 4a and Figure 4b Shows Figure 3 An interior view of the evaporator article is shown.

[0011] Figure 5 Another example of an evaporator article constructed according to one aspect of the present disclosure is shown.

[0012] Figure 6a and Figure 6b Shows Figure 5 An interior view of the evaporator article is shown.

[0013] Figure 7 Another example of a cartridge (media storage element) constructed in accordance with one aspect of the present disclosure is shown.

[0014] Figure 8a An example of an atomizer constructed in accordance with one aspect of the present disclosure is shown.

[0015] Figure 8b and Figure 8c An example of a cartridge constructed in accordance with one aspect of the present disclosure is shown.

[0016] Fig. 9 Another example of an atomizer constructed in accordance with one aspect of the present disclosure is shown.

[0017] Fig.10 Another example of an atomizer constructed in accordance with one aspect of the present disclosure is shown.

[0018] Fig.11 Another example of an atomizer constructed in accordance with one aspect of the present disclosure is shown.

[0019] Fig.12 Another example of an atomizer constructed in accordance with one aspect of the present disclosure is shown.

[0020] Fig.13 Another example of an atomizer constructed in accordance with one aspect of the present disclosure is shown.

[0021] Fig.14a , Fig.14b Additional exemplary configurations of cartridges constructed in accordance with aspects of the present disclosure are shown.

[0022] Fig.14c Another example of an evaporator article constructed according to one aspect of the present disclosure is shown.

[0023] Fig.14d and Fig.14e An example of a cartridge constructed in accordance with one aspect of the present disclosure is shown.

[0024] Fig.15a An example of an electronic circuit constructed according to one aspect of the present disclosure is shown.

[0025] Fig.15b Another example of an electronic circuit constructed according to one aspect of the present disclosure is shown.

[0026] Fig.16a An example of data that may be programmed into a cartridge component according to one aspect of the present disclosure is shown.

[0027] Fig.16b An example of data that may be programmed into a cartridge component and a database according to one aspect of the present disclosure is shown.

[0028] Fig.17a An example of how to control the dispensing and evaporation of an inhalation medium according to one aspect of the present disclosure is shown.

[0029] Fig.17b Exemplary details of how to control the dispensing and evaporation of an inhalation medium according to one aspect of the present disclosure are shown.

[0030] Fig.17c Alternative exemplary details of how to control the dispensing and evaporation of an inhalation medium according to one aspect of the present disclosure are shown.

[0031] Fig.17d Alternative exemplary details of how to control the dispensing and evaporation of an inhalation medium according to one aspect of the present disclosure are shown.

[0032] Fig.18 An example of a networked system for exchanging data according to one aspect of the present disclosure is shown.

[0033] Fig.19 An example of how usage data is generated according to one aspect of the present disclosure is shown.

[0034] Fig. 20 An example of how effect and dosing recommendations may be determined and communicated according to one aspect of the present disclosure is shown.

[0035] Fig.21a An example of how to display cartridge information according to one aspect of the present disclosure is shown.

[0036] Figure 21b Another example of how to display cartridge information according to one aspect of the present disclosure is shown.

[0037] Fig.21c An example of how to generate a dosing control according to one aspect of the present disclosure is shown.

[0038] Fig.22a Another example of information that may be used to inform dosing control according to one aspect of the present disclosure is shown.

[0039] Figure 22b Another example of how to generate a dosing control according to one aspect of the present disclosure is shown.

[0040] Fig.23 Another example of how to generate a dosing control according to one aspect of the present disclosure is shown.

[0041] Fig.24a and Figure 24b Additional examples of evaporator articles constructed according to one aspect of the present disclosure are shown.

[0042] Fig.25 An example of a solid media evaporator article constructed in accordance with one aspect of the present disclosure is shown.

[0043] Fig.26 Another example of a solid media evaporator article constructed in accordance with one aspect of the present disclosure is shown.

[0044] Fig.27a An exemplary response curve to a drug is shown.

[0045] Figure 27b Exemplary response curves to various doses of drug are shown.

[0046] Fig.28 A model or equation that can improve a response curve to a drug according to one aspect of the present disclosure is shown.

[0047] Fig.29a , Fig.29b and Fig.29c An example of how to configure a time-based and intensity-based dosing interface for an evaporator article according to one aspect of the present disclosure is shown.

[0048] Fig.30a , Fig.30b and Fig.30c Further examples of how to construct time-based and intensity-based dosing interfaces according to one aspect of the present disclosure are shown.

[0049] Fig.31 Another example of how to generate a dosing control according to one aspect of the present disclosure is shown.

[0050] Fig.32a , Figure 32b and Fig.32c An example of a dosage feedback and shared interface for a vaporizer article constructed in accordance with one aspect of the present disclosure is shown.

[0051] Fig.33a , Fig.33b and Fig.33c

[0046] Additional examples of dosage feedback and sharing interfaces constructed in accordance with one aspect of the present disclosure are shown.

[0052] Fig.34a , Fig.34b and Fig.34c Additional examples of interfaces constructed according to one aspect of the present disclosure are shown.

[0053] Fig.35a and Fig.35b Another example of an evaporator article constructed according to one aspect of the present disclosure is shown.

[0054] Fig.36a , Fig.36b and Fig.36c An example of an alternative delivery pathway device constructed in accordance with one aspect of the present disclosure is shown.

[0055] Fig.37a , Figure 37b and Fig.37c An example of how to generate a cessation dosing control according to one aspect of the present disclosure is shown.

[0056] Fig.38a , Figure 38b and Fig.38c A further example of how to generate a withdrawal dosing control according to one aspect of the present disclosure is shown.

[0057] Fig.39a and Fig.39b An example of how to generate dosing control and withdrawal control according to one aspect of the present disclosure is shown.

[0058] Fig.40a and Fig.40b An example of how dosing information may be displayed and shared according to one aspect of the present disclosure is shown.

[0059] Fig.41 An example of how dosing information may be generated and shared according to one aspect of the present disclosure is shown.

[0060] Fig.42a , Figure 42b , Figure 42c and Fig.42d An exemplary network system architecture for selecting and executing applications according to one aspect of the present disclosure is shown.

[0061] Fig.43a and Figure 43b An example of how an application may be triggered according to one aspect of the present disclosure is shown.

[0062] Fig.44a and Figure 44b An example of how to generate a dosing control according to one aspect of the present disclosure is shown.

[0063] Figure 44c to Figure 44cc Additional examples of generation controls and displays according to one aspect of the present disclosure are shown.

[0064] Fig.45a and Fig.45b It shows how to construct a sharing interface and perform a sharing connection according to one aspect of the present disclosure.

[0065] Fig.46a and Fig.46b It shows how operating instructions can be communicated according to one aspect of the present disclosure.

[0066] Fig.47a and Figure 47b An example of an alternative delivery pathway device constructed in accordance with one aspect of the present disclosure is shown.

[0067] Figures 48a to 48d An example of how a withdrawal dosing control may be generated according to one aspect of the present disclosure is shown. DETAILED DESCRIPTION

[0068] The present disclosure and its various features and advantageous details are more fully described with reference to the non-limiting embodiments and examples described and / or shown in the accompanying drawings and described in detail below. It should be noted that the features shown in the drawings do not have to be drawn to scale, and even if not explicitly stated herein, those skilled in the art will recognize that the features of one embodiment can be used with other embodiments. The description of well-known components and processing techniques can be omitted so as not to unnecessarily obscure the embodiments of the present disclosure. The examples used herein are intended only to facilitate understanding of the ways in which the present disclosure can be practiced, and also to enable those skilled in the art to practice the embodiments of the present disclosure. Therefore, the examples and embodiments herein should not be interpreted as limiting the scope of the present disclosure. In addition, it should be noted that in all the drawings, similar reference numerals represent similar parts.

[0069] Figure 1a The example of evaporator article 10 according to one aspect of the present disclosure is shown. In this example, evaporator article 10 includes control device 100 and medium holding storage box 200. Control device 100 includes housing 101, which is configured to hold certain parts, and its shape and size enable users to easily hold and carry evaporator article 10. Housing 101 can be made of injection molded plastic, metal or other common engineering materials generally. Control device 100 has storage box receiving area 102 designed to cooperate with storage box 200. Storage box 200 includes storage box housing 201, which is configured to hold certain parts and inhale medium. Storage box housing 201 can generally contain injection molded plastic, metal or other common engineering materials. Because the inner part of storage box housing 201 can be in direct contact with inhalation medium, the material of storage box housing is selected to minimize the possible chemical reaction with inhalation medium. In this example, the control device 100 is configured to cooperate with one cartridge 200, however, it should be noted that in other embodiments, the control device 100 can be configured to receive and dispense inhalation media from multiple simultaneously connected cartridges 200 in an independently addressable manner. Alternatively, the cartridge 200 can be configured to have multiple inhalation media storage areas 206 and a plunger 204 that is configured to work with the control device 100 capable of dispensing inhalation media from such a configured cartridge 200.

[0070] The control device 100 has a charging connector 103, which can be connected to a power source to charge the battery 111, such as Figure 2As shown. The control device 100 may also include a plurality of indicator lights 104a to 104e. In this example, the indicator light 104a is used to indicate when the control device 100 is being charged via the charging connector 103. For example, when the battery 111 is being charged, the indicator light 104a may glow red, and when charging is complete, the indicator light may go out. The indicator light 104b may be used to indicate the state of charge of the battery 111. In this example, the indicator light 104b may change from green when fully charged to red when fully discharged. In other embodiments, the indicator light 104b may be replaced by a light bar that indicates the charge level of the battery 111.

[0071] The control device 100 is configured to deliver a precise dose of the inhalation medium stored in the cartridge 200. Figure 1a In the example shown, the user selects the dose by turning the dose selector dial 105. The housing 101 may include a dose level mark 106 to help the user set the dose level. In other embodiments, the dose level mark 106 may be accompanied by text or an icon indicating the amount of medium to be dispensed. Once the user has selected the desired dose, he can press the dosing button 107a. When the dosing button 107a is pressed, a precise amount of medium is transferred to the evaporator element 109 through the storage box outlet 202, an example of which will be described below. When the medium is transferred, the indicator light 104c can be lit to indicate that the medium is being transferred. In addition, the indicator light 104c can be lit in different ways to indicate when the medium has been fully transferred. For example, it can be lit in different colors and / or in a flashing mode. If the dosing button 107a is pressed, but the previous dose of the medium has not been evaporated by the evaporator element 109, the control device 100 can be configured not to transfer the medium to the evaporator element 109. In this case, the indicator light 104c can be lit in different colors or modes to indicate that the dose has been transferred. In other embodiments, indicator light 104c may be configured to not illuminate to indicate that no more media is being transferred.

[0072] Once the medium has been fully delivered, the user can activate the vaporizer element 109 by placing a portion of the evaporation article 10 in the mouth and inhaling through the vapor outlet 110. When the user inhales, an electric current is provided to the vaporizer element 109, which heats it and evaporates the inhalation medium present on the vaporizer element 109. The vapor combines with the air to form an aerosol, which is inhaled by the user. After repeated doses and inhalations, the inhalation medium in the storage box 200 can be completely consumed. At this point, the user can replace the empty storage box 200 with a newly filled storage box 200 by first pressing the storage box release button 107b to start the release process. The indicator light 104e can indicate when the release process is performed by flashing in a certain mode, and then light up in a stable manner when the release process is completed and the storage box 200 is ready to be removed. Alternatively, the indicator light 104e can change color to indicate the release process action and completion. It should be noted that the user does not necessarily have to wait until the storage box 200 becomes empty before replacing the storage box. For example, if a user wishes to swap between 2 different cartridges 200 containing different inhalation media, the user may employ the release process to enable the swap.

[0073] The control device 100 has the ability to send information to a computing device. Suitable communication methods include, but are not limited to: USB, Bluetooth, Zigbee, Wi-Fi, and digital cellular. In a preferred embodiment, Bluetooth is used to exchange data with a mobile computing device. In this case, the indicator light 104d can be used to indicate the communication status. For example, when pairing, the indicator light 104d can flash or alternate between different colors. After the communication link is established, the indicator light 104d can be lit with a steady color. When the communication is closed, the indicator light 104d can be extinguished.

[0074] Figure 1b and Figure 1c An alternative embodiment of a vaporizing article 10 is shown, which includes a control device 100 and a cartridge 200. In this example, the housing 101 has a shape that is easy to hold and operate. The inhalation outlet 110 is located within a mouthpiece 128. The mouthpiece 128 may be permanently fixed to or integral with the housing 101, or in other embodiments may be removable to allow other users to share the same control device 100 in a more sanitary manner by using their own mouthpiece 128. Figure 1b and Figure 1cIn the illustrated embodiment, alignment features 126a and 126b are provided to allow easy alignment of cartridge 200. Cartridge 200 has corresponding mating features (not shown) shaped to receive alignment features 126a and 126b. Control device 100 may also include magnet 127 for helping retain cartridge 200 by magnetic attraction to a magnet (not shown) or ferrous metal sheet (not shown) located within cartridge 200. Alternatively, a magnet may be located within cartridge 200 and the ferrous metal may be located within housing 101. Figure 1b and Figure 1c In the illustrated embodiment, the cartridge housing 201 includes a viewing window 207 to allow the user to see the inhalation medium, thereby understanding the nature and / or amount of the inhalation medium present in the cartridge 200. The viewing window 207 may include an opening in the cartridge housing 201 for viewing a transparent portion of the cartridge housing 201 that contains the inhalation medium. The transparent portion of the cartridge housing 201 may be integral with the cartridge housing 201, or may be comprised of a plurality of separate components that are assembled to form the viewing window 207.

[0075] The control device 100 can be incorporated with a display screen 129 and a control panel 130. The display screen can display information and provide device control, including but not limited to: the amount of inhaled medium remaining in the storage box 200, the state of charge of the battery 111, the state of wireless communication, the amount of inhaled medium to be dosed, the characteristic information about the inhaled medium, the operating state of the control device 100, the response to the dosing command, the dosing option, the dosing input, health statistics, advertisements, brand logos, command input options, screen brightness control, charging options, vaporizer settings, maintenance functions, message notifications, messages, dosage sharing options, social media messages and power options. In this embodiment, the display screen can replace one or more functions of indicator lights 104a to 104e. The user interacts with the control device 100 through the control panel 130. The control panel 130 can replace the function of the dosage selector dial 105 and / or buttons 107a and 107b. The control panel 130 can be used to navigate the information displayed on the display screen 129, select what information to display, and provide input to the control device 100. The control pad 130 may include a rigid or semi-rigid portion covering one or more switches (not shown) configured to detect menu navigation and selection inputs. Alternatively, the control pad 130 may be a capacitive or pressure sensing surface capable of detecting the position of a user's finger and / or gestures generated by the movement of the user's finger, and capable of interpreting such inputs for navigating and / or selecting items on the display screen 129. In certain embodiments, the control pad 130 may be equipped with a fingerprint reading sensor that may be used to unlock / enable the control device 100 based on a list of authorized users and associated fingerprints stored in the memory 1503. In an alternative embodiment, the display screen 129 is touch-sensitive, thereby allowing the user to navigate and / or select items directly on the display screen 129, thereby eliminating or reducing the need for the control pad 130. In such an embodiment, the user may also unlock / enable the control device 100 by entering / drawing a security pattern associated with an authorized user on the display screen 129.

[0076] Figure 2The cross-sectional view of the embodiment of the control device 100 and storage box 200 of Fig. 1 is shown.The control device 100 includes a control circuit 120, which controls the operation of the control device 100.The control circuit 120 is connected to the charging connector 103 to receive power and charge the battery 111.The control circuit 120 accepts input from buttons 107a and 107b and the dosage selector dial 105, and can be configured to accept input from the control board 130 instead.The control circuit controls the operation of indicator lights 104a to 104e, and can also be configured to drive display screen 129.When the control circuit 120 receives the dosing level command related to the target dose, it determines the required drive signal when the required inhalation medium is transferred, distributed, delivered, etc. The inhalation medium is transferred by the action of the plunger driver 116, and the plunger driver moves the plunger 204 to a determined distance, so that the volume of the inhalation medium storage area 206 is changed to a determined amount, thereby forcing the inhalation medium of an accurate amount to pass through the storage box outlet 202. When the cartridge 200 is mated with the control device 100, the plunger driver 116 is aligned with the driver opening 203 and the plunger 204. The plunger driver 116 may have an internally threaded portion connected to the drive screw 115. Figure 2 In the illustrated embodiment, the plunger driver 116 is not coaxial with the drive screw 115, however, an alternative embodiment of the plunger driver 116 consists of a coaxial configuration in which the plunger driver 116 completely surrounds all but one end of the drive screw 115 when in the fully retracted position. Figure 2 In the embodiment shown, the drive screw 115 is constrained by the housing 101 in all degrees of freedom except for rotation about its main axis. The drive screw 115 is rigidly connected to the driven gear 114, or alternatively can be formed integrally with the driven gear 114. The driven gear 114 is driven by the drive gear 113, which is in turn rigidly connected to the motor shaft 117 of the dispensing motor 112. It should be noted that the drive gear 113 can be replaced by a series of gears or a gearbox with multiple gear stages to obtain the torque required for the drive system. This torque amplification through the gear transmission scheme is adopted so that a small motor can be used while still delivering sufficient driving force at the plunger driver 116. If size restrictions are not considered, or a motor with sufficiently large torque can be obtained within the size restrictions, the gears can be omitted and the plunger driver 116 can be driven directly from the dispensing motor 112.

[0077] The optical encoder disk 118 is connected to the motor shaft 117. The optical encoder disk 118 can be connected to the drive gear 113 side of the dispensing motor 112, or can be connected to the opposite end of the dispensing motor 112, provided that a portion of the motor shaft 117 extends beyond the non-gear side of the housing of the dispensing motor 112. In other embodiments, the optical encoder disk 118 can be mounted to the drive screw 115 or gear, however, mounting the optical encoder disk 118 to the motor shaft 117 may be preferred because it provides a higher resolution determination of the position of the plunger driver 116 due to the gear ratio between the drive gear 113 and the plunger driver 116. The optical encoder disk 118 includes a series of equally spaced and sized openings that allow the light detector 122 to receive light from the emitter 121 when the openings are aligned with the emitter 121, and when the openings are not aligned with the emitter, the light from the emitter 121 will be blocked. When the motor shaft 117 rotates, the light detector 122 will generate a digital signal, wherein the rate at which the digital signal switches corresponds to the rotation rate of the motor shaft 117. Since the emitter 121 and the light detector 122 are electrically connected to the control circuit 120, the control circuit 120 can use the rate information to calculate the extent to which the motor has rotated, thereby calculating the distance that the plunger driver 116 has traveled. Alternatively, the control circuit 120 can be configured to use the position information instead of the rate information from the light detector 122 to determine the distance that the plunger driver 116 has traveled. For example, using the fact that the rotation of the optical encoder disk 118 from one opening (or closure) to the next opening corresponds to a known amount of travel of the plunger driver 116, the control circuit 120 (which is electrically connected to the dispensing motor 112) can activate the dispensing motor 112 and begin counting the number of openings (or closures) detected by the light detector 122 until the number of desired openings (or closures) corresponding to the desired plunger driver 116 stroke has been reached. Once this is achieved, the control circuit 120 can terminate the drive signal to the dispensing motor 112. In this way, the control circuit 120 has determined how far to drive the plunger driver 116 in order to deliver the requested amount of inhalation medium, and controls the motor to achieve that stroke, dispensing a precise dose onto the vaporizer element 109 .

[0078] The foregoing description describes a system that uses a specific style of transmission system and a specific style of sensor to achieve a dosing function. Alternative methods can be used to achieve this function. For example, the dispensing motor 112 can be a stepper motor, whereby the drive signal determines the incremental advance of the motor shaft 117, thereby eliminating the need for the optical encoder disk 118, the transmitter 121, and the light detector 122. Alternatively, the dispensing motor 112 can be a linear motor. In this case, the linear motor can be directly connected to the plunger driver 116, or it can be connected through a linear transmission system. Moreover, in addition to the geared transmission system, the system can also use a linkage, a belt and pulley, or a cable drive to connect the plunger driver 116 to the dispensing motor 112. The optical encoder disk 118, the transmitter 121, and the light detector 122 can be replaced by a Hall effect sensor, wherein the Hall effect magnet partially replaces the optical encoder disk 118 and is mounted to a portion of the motor shaft 117. The Hall effect magnet can have one or more sets of magnetic poles. In this case, one or more Hall effect sensors in place of the light detector 112 may be mounted to a fixed portion of the dispensing motor 112, a fixed PCB or a fixed portion of the housing 101 and configured to detect the rotation of the Hall effect magnet. The Hall effect sensor may provide substantially the same functionality to the control circuit 120 as that provided by the light detector 122. Alternatively, the optical encoder disk 118, the emitter 121 and the light detector 122 may be replaced by a potentiometer attached to a portion of the motor shaft 117. Alternatively, an optical linear encoder, a linear Hall effect sensor or a linear potentiometer may be mounted to or integrally formed with the plunger drive 116.

[0079] After the dose has been delivered to the vaporizer element 109, the user can trigger vaporization by inhaling through the inhalation outlet 110. When the user inhales, the inhalation sensor 119 detects the corresponding pressure change. The signal is read by the control circuit 120, which in turn activates the vaporizer element 109. Fresh air can flow into the control device 100 through the air inlet 123. The size of the air inlet 123 can substantially determine the resistance to airflow, otherwise known as "puff resistance". A larger air inlet 123 can produce a lower puff resistance than a smaller air inlet 123. For users trying to imitate the characteristics of a traditional cigarette, the puff resistance may be an important experience characteristic. Having a puff resistance between 2mm 2 and 6mm 2The air inlet 123 of the opening area between can be optimal, to replicate the suction resistance of traditional cigarettes.After air enters via the air inlet 123, air then flows through the upstream channel 125a in the housing 101 and flows through the evaporator element 109, wherein steam initially combines with air to form an aerosol and is brought into the airflow.Then, the aerosol continues to pass through the outlet channel 125b and leaves the housing 101 via the suction outlet 110.The inlet channel 125a and the outlet channel 125b can be integrated with the housing 101, or can be formed by the combination of the housing 101 and the storage box housing 201.The size of the inlet channel 125a and the outlet channel 125b can also be designed to control the suction resistance.The cavity formed by the combination of the storage box housing 201 and the space immediately surrounding the evaporator element 109 can determine the particle or droplet size of the aerosol.The larger the cavity size, the more small vapor droplets accumulate in the aerosol to form larger droplets, thereby forming an aerosol with a larger average particle size. The cavity size may be designed to produce an optimal particle size for absorbing the inhaled medium. An auxiliary air inlet (not shown) may optionally be included at or downstream of the vaporizer element 109 to provide additional air to mix with the aerosol and produce a cooler aerosol for the user to inhale.

[0080] The control device 100 may also include a vibration transducer 124, which may be connected to the control circuit 120. The control circuit 120 may activate the vibration transducer 124 to signal to the user the activation state of the vaporizer element 109 and / or the completion of vaporization of the inhalation medium delivered to the vaporizer element 109. Such non-visual communication with the user may be beneficial because it may be difficult for the user to see visible indicators on the control device 100 during inhalation.

[0081] Storage box 200 can also comprise a readable / writable memory IC 205, such as EEPROM, so that storage information includes but is not limited to: identity information, characteristic, dosing information, control information and usage information of suction medium.Memory IC 205 can be used for tracking the amount of the suction medium previously transmitted and the amount remaining in the suction medium storage area 206.For example, new storage box 200 can comprise memory IC 205, it has been programmed with the numerical value of optical encoder disk 118 counts (limits), and this numerical value corresponds to how far the plunger driver 116 must advance and could completely empty the suction medium storage area 206.When distributing each dosage, the running total of the counting currently distributed can be written to memory IC 205 by control circuit 120.This is completed via one or more electrical connectors 108.This example uses two electrical connectors 108a and 108b, they are electrically communicated with control circuit 120, and are electrically contacted with memory IC 205 when storage box 200 and control device 100 correctly cooperate. Electrical connector 108a and 108b can be flexible metal contacts, spring loaded pins or other compliance conductive contacts.Before, during or after distributing each dose, control circuit 120 can compare the running total of the count that has been distributed with the limit value.When numerical value is equal, control circuit 120 can indicate that storage box 200 is empty.In addition, the running total of the count that is recorded in the memory IC 205 can be used by control circuit 120 to determine that it must retract plunger driver 116 how far can storage box 200 and housing 101 be provided to separate.If before storage box 200 is empty, storage box 200 is separated from control device 100, then user wants to reconnect storage box 200 to consume additional dose later, then control circuit 120 can use the running total of the counting information that is stored in the memory IC 205 to determine how far plunger driver 116 is driven to reestablish contact with plunger 204 before distributing next dose and restarting to add to the running total of count.

[0082] Figure 2 The illustrated embodiment employs a single cartridge 200 and a corresponding dispensing system, however, there are alternative embodiments that can simultaneously accommodate two or more cartridges 200. In these embodiments, there may be a corresponding number of plunger drivers 116, transmissions, and dispensing motors 112. The control circuit 120 may be configured to calculate the amount of inhaled medium to be dispensed from each cartridge 200 onto one or more vaporizer elements 109 and drive the dispensing motor 112 to achieve the desired dose.

[0083] There are other embodiments of the control device 100 in which the evaporation element 109 is omitted. In these embodiments, the medium inside the cartridge will be taken orally rather than inhaled. Such embodiments are configured so that when the medium is transferred from the cartridge 200, the medium is transferred directly into the user's mouth.

[0084] Figure 3 A manual vaporizer article 30 is depicted. The manual vaporizer article 30 is substantially similar to the vaporizer article 10, with the primary difference being that the dispensing of the inhaled medium is accomplished by manual action rather than being driven by the dispensing motor 112. In this embodiment, the components responsible for vaporization, charging, data exchange, and indication may be similar or even identical. Figure 1a The storage box 200 shown in the figure can be used in combination with the control device 100 or the manual control device 300. The manual control device 300 includes a manual housing 303, which can be constructed of injection molded plastics, metal or other common engineering materials. The manual vaporizer product 30 adopts a distribution rod 301, which acts on the drive system inside the manual control device 300. The rod gap space 305 is formed by the gap between the manual housing 303 and the distribution rod 301. This allows the distribution rod 301 to move relative to the manual housing 303. The distribution rod pivots around the rod pivot 302. The manual housing 303 also includes a dose level mark 106 and a manual dose selector dial 304.

[0085] Figure 4a and Figure 4b A cross-sectional view and a detail view of a manual control device 300 are shown. A user interacts with the manual control device 300 by first selecting a dose via a manual dose selector dial 304. The manual dose selector dial 304 can rotate around a single axis established by features in the manual housing 303. The manual dose selector dial 304 has a gear tooth portion that cooperates with a corresponding gear tooth portion of a rotary dose limit stop 310. The rotary dose limit stop 310 rotates around an axis established by features in the manual housing 303 and also includes an off-axis or elliptical portion. When the rotary dose limit stop 310 rotates around the center of its gear portion, the outer surface of its off-axis or elliptical portion moves closer to or away from the drive rack 306. In this way, the rotary dose limit stop 310 determines the extent to which the drive rack 306 can travel. When the user depresses the dispensing lever 301, which is connected to the drive rack 306 by a rotary joint 307, the drive rack 306 rotates the pinion 308, which in turn advances the manual driven rack 309. A manual plunger driver 315, which may be securely connected to the manual driven rack 309 or formed integrally with the manual driven rack, pushes the plunger 204. In this way, the rotational position of the manual dose selector dial 304 controls the amount of inhaled medium delivered to the vaporizer element 109.

[0086] The movement of the drive rack 306 is detected via an emitter 121 and a light detector 122 arranged to detect light passing through a linear encoder window 311, which may be integrally formed or securely secured to the drive rack 306. The emitter 121 and light detector 122 may be formed as a single component having a cutout or area through which the linear encoder window 311 may travel. The signal from the light detector 122 is provided to the control circuit 120. In this manner, the control circuit 120 is presented with signal information that may be used to control the function of the manual control device 300. In some embodiments, a Hall effect sensor and a magnet may be used in place of the light detector 122 and the linear encoder window 311.

[0087] After the user releases the dispensing rod 301, the return spring 313 pushes the dispensing rod 301 back to its initial position. In order to keep the manual plunger driver 315 in its latest position, a ratchet system is provided to allow the drive rack 306 to disengage from the pinion 308. The gear teeth of the drive rack 306 and the pinion 308 are shaped to remain engaged when driven in one direction and disengage when moving in the opposite direction. As the dispensing rod 301 returns to its initial position, the drive rack 306 can pivot around the rotary joint 307, thereby raising its gear teeth and disengaging from the pinion 308. A ratchet spring 314 is provided to push the drive rack 306 back toward the pinion 308 so that when the dispensing rod 301 returns to its initial position, the drive rack can reengage. The ratchet spring 314 is configured as a compression type spring, however, there is an embodiment that can be a tension spring. The return force of the ratchet spring 314 is typically small, thereby providing enough force to facilitate engagement when moving in the dispensing direction, but not providing too much force to prevent disengagement when the drive rack 306 returns to its initial position after dosing.

[0088] Unlike the vaporizer article 10, which electronically controls how much inhaled medium is delivered to the vaporization element, the manual vaporizer article 30 does not prevent the user from placing more inhaled medium on the vaporizer element 109 than can be vaporized at one time or can reasonably be accommodated by the vaporizer element 109. However, this limitation can be mitigated by using the signal from the optical detector 122 to notify the control circuit 120 so that the control circuit can track and notify the user how much inhaled medium has been delivered and when a limit or recommended amount is approached or exceeded.

[0089] Figure 5An alternative embodiment of a manual vaporizer article 30 is shown. Similar to the manual vaporizer article 30, the dispensing of the inhaled medium in the button vaporizer article 50 is accomplished by manual action, rather than being driven by the dispensing motor 112. In this embodiment, the components responsible for evaporation, charging, data exchange, and indication may be similar or even identical. The storage box 200 may be used in combination with any one of the control device 100, the manual control device 300, and the button control device 500. The button control device 500 includes a button housing 503, which may be constructed of injection molded plastic, metal, or other common engineering materials. The button vaporizer article 50 uses a dispensing button 501, which acts on a drive system inside the button control device 500. The button housing 503 also includes a dose level mark 106 and a button dose selector dial 504.

[0090] Figure 6a and Figure 6b The cross-sectional view and detail view of button control device 500 are shown. The user interacts with button control device 500 by first selecting a dose via button dosage selector dial 504. The button dosage selector dial 504 can rotate around a single axis established by button body 501b. The button dosage selector dial 504 has one or more inner grooves 515a, 515b and 515c, each inner groove having an open end toward button key 502, and a closed end on the opposite end of each inner groove 515a to 515c. The closed end of each inner groove 515a to 515c is at different distances from the open end shared by the user. When a specific inner groove (e.g., inner groove 515a) is aligned with button key 502 and the user presses the button tip 501a, the button body 501b can advance to a depth limited by the contact of the closed end of button key 502 and inner groove 515a. When the button dosage selector dial 504 is rotated to align the internal groove 515b with the button key 502 and the user depresses the button tip 501a, the button body 501b can now travel to different depths, which is limited by the contact of the button key 502 with the closed end of the internal groove 515b.

[0091] When the user presses the button tip 501a, the button body 501b moves the button drive rack 505. The button body 501b is connected to the button drive rack 505 via the button rotary joint 506. As the button drive rack 505 advances, the button drive gear 509 and the button driven gear 510 rotate, which in turn advances the button driven rack 511. The button plunger driver 514, which can be firmly connected to the button driven rack 511 or formed integrally with the button driven rack, pushes the plunger 204. In this way, the rotational position of the manual dose selector dial 504 controls the amount of inhaled medium delivered to the vaporizer element 109.

[0092] Movement of the button follower rack 511 is detected via an emitter 121 and a light detector 122 arranged to detect light passing through a button linear encoder window 513, which can be integrally formed or securely secured to the button follower rack 511. The emitter 121 and the light detector 122 can be formed as a single component having a cutout or area through which the button linear encoder window 513 can travel. The signal from the light detector 122 is provided to the control circuit 120. In this manner, signal information that can be used to control the function of the button control device 500 is presented to the control circuit 120. In some embodiments, a Hall effect sensor and a magnet can be used instead of the light detector 122 and the button linear encoder window 513.

[0093] After the user releases the button tip 501a, the button return spring 508 pushes the button drive rack 505 back to its initial position. In order to keep the button plunger driver 514 in its latest position, a ratchet system is provided to allow the button drive rack 505 to disengage from the button drive gear 509. The gear teeth of the button drive rack 505 and the button drive gear 509 are shaped to remain engaged when driven in one direction and disengage when moving in the opposite direction. When the button body 501b returns to its initial position, the button drive rack 505 can pivot around the button swivel 506 so that its gear teeth rise and disengage from the button drive gear 509. A button ratchet spring 507 is provided to push the button drive rack 505 back toward the button drive gear 509 so that the drive rack can reengage when the button body 501b returns to its initial position. The button ratchet spring 507 is configured as a compression type spring, however, there is an embodiment that can be a tension spring. The return force of the button ratchet spring 507 is typically small, thereby providing enough force to facilitate engagement when moving in the dispensing direction, but not providing too much force to prevent disengagement when the button drive rack 505 returns to its initial position after dosing.

[0094] Figure 7 Shown is a cross-sectional view of an alternative embodiment of cartridge 200. In this embodiment, cartridge housing 201 has an inner portion that accommodates a flexible suction medium bag 701 that is connected to cartridge outlet 202. Suction medium is stored in suction medium bag 701. In this embodiment, plunger driver 116 is directly pressed on suction medium bag 701, so as to transmit suction medium via cartridge outlet 202. The material of suction medium bag 701 is selected to minimize possible chemical reactions with suction medium.

[0095] Figure 8aAn evaporator element 109 constructed according to one aspect of the present disclosure is shown. In this embodiment, the evaporator element 109 includes a heating element 801, a substrate 802, and heater leads 803a and 803b. The substrate 802 can be constructed using a thin sheet of ceramic, glass, or other material that conducts heat well but conducts current poorly. An example size of the substrate 802 is 6mm×6mm×1mm. By keeping the substrate 802 thin, heat energy can be more easily transferred from the heating element 801 to the surface of the substrate 802 closest to the storage box outlet 202. Keeping the substrate 802 thin enables the use of materials such as glass, which does not conduct heat as quickly as other suitable materials. The heating element 801 includes a resistive heating element that generates heat when an electric current passes through the material. The heating element 801 can be a resistive compound that is deposited on one or more surfaces of the substrate 802 using a deposition technique commonly used in the manufacture of electronic components. Alternatively, the heating element 801 can be a resistance wire formed into a flat shape and in contact with one or more surfaces of the substrate 802 or embedded in the substrate 802. Typical resistance wire materials include nickel-chromium alloy, titanium, Kanthal and other suitable materials. The typical resistance value of the heating element 801 is in the range of 0.1 ohm to 5 ohms.

[0096] Heater leads 803a and 803b provide electrical connection between heater element 801 and control circuit 120. Heater leads 803a and 803b can be soldered, welded or otherwise mechanically kept in contact with heater element 801. Substrate 802 is located near cartridge outlet 202, preferably not in contact. By keeping close to state, a small amount or droplet of suction medium can bridge the distance between cartridge outlet 202 and substrate 802, and then spread on the surface of substrate 802. Except that droplet can bridge, the contactless close condition also ensures that cartridge outlet 202 neither damages substrate 802, nor can it be coupled with substrate heat, thereby ensures that system will not waste energy to heat cartridge outlet 202 and the parts physically connected with it. The typical distance between substrate 802 and cartridge outlet 202 is in the scope of 0.1mm to 1.0mm. The distance may also be adjusted based on the viscosity of the intake medium; an intake medium with a lower viscosity may not be able to bridge a larger gap and thus require a smaller gap to reliably bridge from the outlet 202 to the substrate 802 .

[0097] To accommodate a range of viscosities of the inhalation medium, the diameter of the cartridge outlet 202 may be sized according to the viscosity of the inhalation medium. Figure 8b and Figure 8cTwo exemplary embodiments of cartridge outlet 202 are shown.For example, the size of cartridge outlet 202a and cartridge outlet inner diameter 805a can be designed to be larger for the larger suction medium of viscosity.Larger size allows suction medium to pass without excessive resistance, and excessive resistance may cause the need to produce larger distribution motor 112, drive gear 113 and / or gear box of greater force.Must be careful, make cartridge outlet inner diameter 805a should not be too large, so as not to allow suction medium to leak when no pressure is applied to plunger 204.The optimum size of given viscosity suction medium can be determined by carrying out one or more in static, vibration, ambient pressure cycle and temperature cycle test on multiple orientations, for example, cartridge outlet 202 orientations are oriented in the orientation below the suction medium storage area 206, so that gravity can be used for suction medium being discharged from cartridge outlet 202, and then selects the maximum size that does not leak.The typical cartridge outlet 202 that size is designed to work with the suction medium of higher viscosity can be in the scope of 10G to 20G. In contrast, the size of cartridge outlet 202b and cartridge outlet inner diameter 805b can be designed to be less, so that in the situation of the suction medium of lower viscosity, suitably work.Less size can reduce the ability of suction medium leakage.The typical cartridge outlet 202 that size is designed to work with the suction medium of lower viscosity can be in the scope of 20G to 28G.The tip of cartridge outlet also can be shaped or cut at a certain angle, and can not leak to further support the bridging of droplet.

[0098] Fig. 9A cylindrical evaporator element 900 is shown that can be used as the evaporator element 109, and it should be understood that future references to the evaporator element 109 can be replaced by the cylindrical evaporator element 900 without affecting the function. The cylindrical evaporator element 900 includes a cylindrical heater 901 and a heater core 902. The cylindrical evaporator element 900 can be oriented so that the airflow caused by the user's inhalation can flow through the surface of the cylindrical evaporator element 900 in a direction substantially parallel to or orthogonal to the main axis of the heater core. The cylindrical heater 901 can be constructed using a resistive wire. When formed by a resistive wire, the ends of the cylindrical heater 901 can be used as electrical connections in the same manner as the heater leads 803a and 803b. Alternatively, a dedicated low-resistance wire (not shown) can be connected to the cylindrical heater 901 and as close to the heater core 902 as possible. Doing so maximizes efficiency and ensures that only the portion of the cylindrical heater 901 that contacts the heater core 902 becomes hot. The heater core 902 can be made of ceramic, glass or other materials. When constructed by non-porous materials, the surface of the heater core 902 can be smooth. In this case, the suction medium can diffuse to form a thin layer covering the outer surface of the heater core 902. The typical resistance value of the cylindrical heater 901 is in the range of 0.1 ohms to 5 ohms. Similar to the evaporator element 109, when the storage box outlet 202 is very close to the cylindrical evaporator element 900, the cylindrical evaporator element 900 plays the best role. Alternatively, the cylindrical heater 901 can be formed on the surface of the heater core 902 by depositing a resistive compound. In this embodiment, a heater lead (not shown) can be provided to establish an electrical connection with the control circuit 120. In another alternative embodiment, the heater core 902 is made of a porous material, such as porous ceramics, non-conductively treated metal mesh, cotton, twisted or woven silica or other similar materials. The cylindrical heater 901 may be wrapped around the heater core 902, or may be integrally formed such that the cylindrical heater 901 is embedded in the heater core 902. By using a porous material for the heater core 902, an increased amount of the drawn medium may be dispensed onto the cylindrical evaporator element 900 at any one time due to the porous material's ability to store liquid. The porous material also allows the drawn medium to diffuse from the dispensing location by capillary action.

[0099] Fig.10A central hole cylindrical evaporator element 1000 is shown that can be used as an evaporator element 109, and it should be understood that future references to the evaporator element 109 can be replaced by the central hole cylindrical evaporator element 1000 without affecting the function. The central hole cylindrical evaporator element 1000 can be constructed of similar materials as the cylindrical evaporator element 900. The central hole heater core 1002 has a through hole 1003 that passes axially through the central hole heater core 1002. It also has a central hole 1004 that provides an opening through which the cartridge outlet 202 can dispense the inhalation medium into the through hole 1003. When the cylindrical heater 901 is powered on, the central hole heater core 1002 heats up, thereby evaporating the inhalation medium that has been dispensed into the through hole 1003. The airflow caused by the user's inhalation can flow through the through hole 1003, thereby carrying away the evaporated inhalation medium that has begun to mix with the air to form an aerosol.

[0100] Fig.11 A through-hole cylindrical evaporator element 1100 is shown that can be used as the cylindrical evaporator element 109, and it should be understood that future references to the evaporator element 109 can be replaced by the through-hole cylindrical evaporator element 1100 without affecting the function. The through-hole cylindrical evaporator element 1100 can be constructed of similar materials as the cylindrical evaporator element 900. The through-hole heater core 1102 has an axial through-hole 1103 that axially passes through the through-hole heater core 1102. The cartridge outlet 202 can distribute the inhalation medium into the axial through-hole 1103. When the cylindrical heater 901 is powered on, the through-hole heater core 1102 heats up, thereby evaporating the inhalation medium that has been distributed into the axial through-hole 1103. The airflow caused by the user's inhalation can flow through the axial through-hole 1103, thereby carrying away the evaporated inhalation medium that has begun to mix with the air to form an aerosol. Alternatively, if the through-hole heater core 1102 is made of a porous material, the suction medium can travel from the axial through-hole to the outer surface of the through-hole heater core 1102, where the suction medium can be evaporated and entrained by an airflow substantially parallel to or orthogonal to the main axis of the through-hole heater core 1102. In another embodiment, in the case of using a porous material, one or both ends of the through-hole heater core 1102 can taper to a point or surface that is designed to receive droplets of the suction medium distributed from the cartridge outlet 202. The suction medium can be spread from this point or surface to the entire through-hole heater core 1102 by capillary action. This point or surface allows the cartridge outlet 202 to be positioned slightly away from the cylindrical heater 901, thereby minimizing the exposure of the cartridge outlet to high temperatures. This point or surface can also be a convenient geometric reference feature for positioning the through-hole cylindrical evaporator element 1100 relative to the cartridge outlet 202.

[0101] Fig.12A composite cylindrical evaporator element 1200 is shown that can be used as a cylindrical evaporator element 109, and it should be understood that future references to the evaporator element 109 can be replaced by the composite cylindrical evaporator element 1200 without affecting the functionality. The composite cylindrical evaporator element 1200 can be constructed of materials similar to the cylindrical evaporator element 900. The outer core 1205 has a composite through hole 1203 that passes axially through the outer core 1205. The cylindrical heater 901 and the composite heater core 1202 are located in the composite through hole 1203. The outer core 1205 also has a composite through hole 1204, through which the cartridge outlet 202 can dispense the inhalation medium. The airflow caused by the user's inhalation can flow through the composite through hole 1203, thereby taking away the evaporated inhalation medium that has begun to mix with the air to form an aerosol. In the primary embodiment of the composite cylindrical evaporator element 1200, the suction medium is distributed onto the composite core 1202, which is used to provide support for the cylindrical heater 901 and to provide a surface for dispersing the suction medium. In an alternative embodiment of the composite cylindrical evaporator element 1200, the composite heater core 1202 is omitted and the suction medium is distributed onto the inner wall of the outer core 1205, which can be in direct contact with the cylindrical heater 901.

[0102] Fig.13 A crucible evaporator element 1300 is shown that can be used as the evaporator element 109, and it should be understood that future references to the evaporator element 109 can be replaced by the crucible evaporator element 1300 without affecting the functionality. The crucible evaporator element 1300 includes a crucible heater 1301 and a crucible core 1302. The crucible heater 1301 is substantially similar to the cylindrical heater 901, with the main difference that its shape is designed to dock with the crucible core 1302. Like the cylindrical heater 901, the crucible heater can be made of resistance wire, chemical deposition, or other previously described methods. The crucible evaporator element 1300 can be constructed of materials similar to the cylindrical evaporator element 900. The crucible core 1302 can have a shape substantially similar to a hemisphere with a hollow area 1304, into which the inhaled medium can be dispensed. When the crucible heater 1301 is powered on, the hollow area 1304 heats up, thereby evaporating the dispensed inhaled medium. Alternatively, if crucible core 1302 is constructed using a porous material, the inhaled medium can travel through the wall of crucible core 1302 where it can contact crucible heater 1301 and evaporate.

[0103] Over extended use, the heat transfer performance of the evaporator element 109 may degrade, particularly if residue from the suction medium accumulates on the surface of the evaporator element 109. Additionally, if a user switches from one cartridge 200 containing one type of suction medium to a different cartridge 200 containing a different type of suction medium, some residual suction medium from the first cartridge 200 may remain on the evaporator element 109.

[0104] Fig.14a An integrated storage box 1400 is shown, which incorporates an evaporator element 109 into its structure. This means that the evaporator element 109 is omitted from the control device 100. This alleviates the above two problems. Additional electrical contacts similar to electrical contacts 108a and 108b can be provided to establish an electrical connection between the integrated storage box 1400 and the control device 100. The integrated storage box 1400 includes an integrated storage box housing 1401, which provides a structure and establishes an integrated medium storage area 1406. Along with the movement of the plunger 204, the volume of the integrated medium storage area 1406 is reduced, thereby forcing the inhaled medium to flow out from the integrated storage box outlet 1402 (its structure and material are similar to the storage box outlet 202) and flow to the evaporator element 109. It should be understood that the evaporator element 109 may be replaced by any of the cylindrical evaporator element 900 , the center hole cylindrical evaporator element 1000 , the through hole cylindrical evaporator element 1100 , the composite cylindrical evaporator element 1200 , or the crucible evaporator element 1300 without affecting the functionality.

[0105] The integrated storage box 1400 may also include an integrated air flow path 1403, whereby the airflow caused by the user's inhalation is directed from the control device 100 through the evaporator element 109, and then returned through the control device 100 toward the vapor outlet 110. A sealing surface (not shown) may be added between the control device 100 and the integrated storage box 1400 to better ensure that air and aerosol flow through the desired path. For the aforementioned purpose, the integrated storage box 1400 may also include a memory IC 205. In an alternative embodiment of the integrated storage box 1400, the plunger 204 and the integrated storage box outlet 1402 may be preassembled with an independent media storage component 1404 (not shown) to form an independent media pre-assembly 1405. The independent media storage component 1404 may be substantially tubular in nature, one end of which is designed to receive the plunger 204, and the other end is designed to dock with the integrated storage box outlet 1402. For ease of assembly, the individual media pre-assembly 1405 may be filled with an intake medium, purged of excess air, and then inserted into the integrated cartridge housing 1401. The integrated cartridge housing 1401 may provide one or more one-way retention features to prevent the individual media pre-assembly 1405 from being removed once fully inserted.

[0106] Fig.14b A cross-sectional view of an evaporator cartridge 10 is shown, which includes an inline cartridge 1420 and an inline control 1410. This embodiment is functionally similar to the previously described system, with the main difference being that the inline cartridge 1420 is positioned inline between the inline control 1410 and the user's mouth. The inline cartridge 1420 may include an inline housing 1421, which is configured to receive a plunger 204 and a cartridge outlet 202. The inline housing 1421 provides an inline media storage area 1422 and forms an outlet channel 1423, which directs the inhaled media to the cartridge outlet 202 when the plunger 204 is pressed down by the inline control 1410. The inhaled media is delivered to the evaporator element 109 in the inline control housing 1411 region. Air enters the inline control housing 1411 via the air inlet 123. The air flows through the evaporator element 109, where it entrains the evaporated inhalation medium that has begun to mix with the air to form an aerosol into the airflow, and then proceeds toward the inline vapor outlet 1425 via the vapor return channel 1424 provided in the inline housing 1421. A seal (not shown) may be provided between the inline cartridge 1420 and the inline control device 1410 to ensure proper air and aerosol flow. Similar to the cartridge 200, the inline cartridge 1420 may also include a memory IC 205.

[0107] Fig.14cA cross-sectional view of a magnetic cartridge 1440 and a magnetic control device 1430 is shown. This embodiment is functionally similar to the previously described system, with the main difference being that the magnetic control device 1430 uses magnetic coupling to drive the plunger 204 in the magnetic cartridge 1440. The magnetic control device housing 1431 is shaped to receive a large portion of the magnetic cartridge housing 1441. The magnetic control housing 1431 may include a retaining feature (not shown) for retaining and aligning the magnetic cartridge 1441. The dispensing motor 112 rotates the drive screw 115, which in turn moves the magnetic driver 1432 up or down in the magnetic housing 1431 according to the direction in which the dispensing motor 112 rotates. The magnetic driver 1432 may be shaped so that it can retain the drive magnet 1433. The drive magnet 1433 may have an annular shape that the magnetic cartridge housing 1441 is suitable for passing through. The drive magnet 1433 may alternatively include a plurality of discrete magnets arranged around the magnetic cartridge housing 1441. The magnetic storage box includes a driven magnet 1435. The driven magnet 1435 can be a single magnet shaped like a plate, or can include a plurality of discrete magnets. The driven magnet 1435 is connected to the plunger 204. The driving magnet 1433 can include driving poles 1433a and 1433b. The driven magnet 1435 can include driven poles 1435a and 1435b. Aim at the aforementioned magnets to provide magnetic coupling so that when the magnetic driver 1432 moves, the plunger 204 follows its movement. In this way, the magnetic control device 1430 can make the suction medium stored in the magnetic storage box medium storage area 1443 be distributed to the evaporator element 109 via the storage box outlet 202, where the suction medium can be evaporated to mix with air to form an aerosol for suction via the magnetic vapor outlet 1442. The magnetic control device 1430 may include one or more electrical connectors 108 (not shown) to provide power to the evaporator element 109 and to be in electrical communication with the memory IC 205 (not shown).

[0108] Fig.14dA partial cross-sectional view of an alternative embodiment of an insertable cartridge 1450 is shown. This embodiment is functionally similar to and combines aspects of an integrated cartridge 1400 and an in-line cartridge 1420. Like the in-line cartridge 1420, the insertable cartridge 1450 is removably connectable from a control device and includes an insertable cartridge vapor outlet 1459 similar to an in-line vapor outlet 1425. Aerosol is intended to flow directly into the user's mouth from the insertable cartridge vapor outlet 1459. And like the integrated cartridge 1400, the vaporizer element 109 is contained in the insertable cartridge 1450. The insertable cartridge 1450 is configured so that the insertable medium storage device 1452 can be filled with an inhalation medium before being inserted into the insertable cartridge housing 1451, as shown in the cross-sectional view. The storage box outlet 202, plunger 204 (not shown) and insertable medium storage device 1452 can be preassembled as a single unit before being inserted into the plug-in storage box housing 1451. Because the outlet of the storage box outlet 202 must be positioned near the evaporator element 109, so that the suction medium contacts with the evaporator element 109, the storage box limit stopper 1458 can be provided to allow the accurate positioning of the storage box outlet 202. Storage box limit stopper 1458a and 1458b can be formed integrally with the plug-in storage box housing 1451. Once the insertable medium storage device 1452 has been assembled, it is also expected that it will be permanently maintained in the plug-in storage box housing 1451. This not only helps to ensure the correct positioning of the storage box outlet 202, but also prevents the user from removing and destroying the insertable medium storage device 1452 and the suction medium. The plug-in storage box housing 1451 can be constructed with a retaining feature (not shown) that permanently maintains the insertable medium storage device 1452, such as a one-way buckle.

[0109] The plug-in storage box housing 1451 may also be provided with one or more electric pads 1454a and 1454b to provide electrical connection between the plug-in storage box 1450 and the embodiment of the control device 100 configured to cooperate with the plug-in storage box 1450. One or more pluggable heater leads 1456a and 1456b provide electrical connection between the electric pads 1454a and 1454b and the evaporator element 109. The pluggable heater leads 1456a and 1456b may be generally constructed of conductive wires, flexible circuits, printed contacts or formed by conductive material sheets (such as metal sheets). It should be understood that, without affecting the function, the evaporator element 109 contained in the plug-in storage box 1450 may be replaced by any one of the cylindrical evaporator element 900, the center hole cylindrical evaporator element 1000, the through hole cylindrical evaporator element 1100, the composite cylindrical evaporator element 1200 or the crucible evaporator element 1300. One or more memory pads 1455a and 1455b may be provided to provide other electrical connection points between the plug-in cartridge 1450 and the control device 100. One or more memory leads 1457a and 1457b connect the memory pads 1455a and 1455b to the memory IC 205. The memory leads 1457a and 1457b may generally be constructed from conductive wires, flexible circuits, printed contacts, or formed from a sheet of conductive material such as a sheet of metal.

[0110] Plug-in storage box 1450 can be configured to comprise one or two in outlet heater 1460 or storage heater 1461 randomly, so that before or during the inhalation medium is distributed on evaporator element 109, heat the inhalation medium.Outlet heater 1460 and storage heater 1461 can be constructed by multiple materials, include but not limited to: resistance film, resistance foil, printing flexible heater, resistance wire, resistance net and the resistance metal formed.By heating inhalation medium before distribution, the viscosity of inhalation medium will reduce, thereby makes it easier to pass through storage box outlet 202.This allows the system to use the inhalation medium of high viscosity relatively.If adopt one or both in outlet heater 1460 or storage heater 1461, then will need to provide additional electrical connection to connect them to the embodiment of the control device 100 that is configured to control outlet heater 1460 and / or storage heater 1461.

[0111] The plug-in cartridge housing may also include a plug-in cartridge airflow inlet 1453 that allows air to enter the plug-in cartridge housing 1451 to mix with the vaporized inhalation medium to form an aerosol. The plug-in cartridge airflow inlet 1453 may also be in fluid communication with the inhalation sensor 119 to signal the control device 100 that the user is inhaling. A seal (not shown) may be provided to ensure good fluid connection between the plug-in cartridge airflow inlet 1453 and the control device 100.

[0112] Fig.14e The view of plug-in storage box 1450 is shown, in which some parts have been hidden, and plug-in airflow path 1462 is shown with a cross-sectional view. When the user inhales, air can enter the plug-in airflow path 1462 via the plug-in storage box airflow inlet 1453. The plug-in airflow path can be formed integrally with the plug-in storage box housing 1451, or can be a separate component. Then, the airflow continues to flow to the evaporator element 109, and this airflow can be further contained in the evaporator chamber 1463, and this evaporator chamber is used to shape the airflow and guide the airflow through the evaporator element 109. The form and size of the evaporator chamber 1463 can be shaped to produce the inhalation medium of a specific particle size with a given air flow rate. After combining with the evaporated medium that has begun to form aerosol in the evaporator chamber 1463, the aerosol is discharged via the plug-in storage box vapor outlet 1459. It should be noted that although some air must flow through the plug-in storage box airflow inlet 1453 so that a signal is generated at the inhalation sensor 119, not all air must flow through the path. If additional air is needed to further dilute the aerosol, an auxiliary air inlet (not shown) may optionally be provided in the plug-in cartridge housing 1451. The auxiliary inlet may be located upstream or downstream of the vaporizer chamber 1463. The auxiliary inlet may be configured to be always open, selectively open, closed, or partially open.

[0113] Fig.15a A vaporizer electrical system 1500 is shown for the vaporizer article 10. The vaporizer electrical system 1500 may include the control circuit 120, buttons 107a-107b, a vibration transducer 124, a vaporizer element 109, an emitter 121, a light detector 122, a charging connector 103, a battery 111, an inhalation sensor 119, a display 129, an indicator light, a memory IC 205, and associated electrical connections.

[0114] The control circuit may include an MCU 1501. The MCU 1501 may be configured to read inputs from a dose selection input circuit 1507, which may be mechanically and / or electrically connected to the dose selector dial 105. The dose selection input circuit 1507 may include a potentiometer and a fixed resistor configured in a voltage divider configuration. When the dose selector dial 105 is rotated, the voltage provided to the MCU 1501 from the dose selection input circuit 1507 changes according to the position of the dose selector dial 105. The MCU 1501 is configured to receive the analog signal and interpret its level as an indication of the amount of the inhaled medium to be dispensed. Alternatively, the dose selection input circuit 1507 may be an optical encoder or a Hall effect sensor and an MCU 1501 as described above.

[0115] The MCU 1501 may also be configured to receive dosing information via a touch interface associated with or overlaid on the display screen 129. The MCU 1501 may also be configured to receive dosing information via a communication interface circuit 1511 that may interface with the two-way radio 1506. For example, a user may input dosing information via a mobile application that communicates with the two-way radio 1506 via an established communication protocol such as Bluetooth, Zigbee, Wi-Fi, or digital cellular.

[0116] MCU 1501 may be configured to send and receive other types of information, including, but not limited to: control device 100 status, button status, user input, usage data, intake media level, intake media characteristics, control device settings, display data, time, battery charge, system health report, and error conditions. MCU 1501 may be configured to store such information in memory 1503. MCU 1501 may also be configured to send and receive the above information via charging connector 103, which may be connected to MCU 1501 via communication interface circuit 1511. For example, communication via charging connector 103 is most commonly accomplished using a USB-type charging connector 103 and associated protocols.

[0117] Once the dosing information has been received and interpreted by the MCU 1501, it calculates the drive signal required for delivering the required dose. When the user presses the dosing button 107a or alternatively requests the dose via the control board 130 or the mobile application, the MCU 1501 provides the drive signal to the bidirectional motor drive circuit 1502, which is electrically connected to the dispensing motor 111. The bidirectional motor drive circuit 1502 may include a transistor arranged in an H-bridge configuration, and may also include a diode and / or a capacitor arranged to minimize electrical noise and reverse current spikes. The drive signal may be an analog signal, may be an "on / off" signal in nature, or may be pulse width modulated (PWM). It may also include multiple signals, such as a direction signal and a speed signal. As described above, while driving the dispensing motor 111, the MCU 1501 may activate the transmitter 121 and monitor the output of the optical detector 122 to control and record the position of the plunger driver 116. If a Hall effect sensor is used instead of the optical detector 122, the position of the plunger driver 116 may be controlled and recorded using an associated signal instead. The MCU 1501 may be configured to write the position of the plunger driver 116 to the local memory 1503 and / or the memory IC 205. The MCU 1501 may also be configured to provide a drive signal that will move the plunger driver 116 in the opposite direction to retract the plunger driver 116 when the user presses the cartridge release button 107b or alternatively requests a release via the control board 130, touch screen, or mobile application.

[0118] After dispensing the required dose, the user can trigger the vaporization of the inhalation medium by inhalation. The inhalation sensor 119 can be configured to detect the pressure change or air flow rate change caused by inhalation. The MCU 1501 can be configured to receive a signal from the inhalation sensor and interpret the signal as an indication that the user wishes to vaporize the inhalation medium. The inhalation signal can be analog or digital. If the inhalation sensor 119 is configured to generate a digital output, the MCU 1501 can interpret it as the presence or absence of an inhalation event. However, if the inhalation sensor 119 is configured to generate an analog output or other output that varies according to the inhalation intensity, the MCU 1501 can be additionally configured to measure the inhalation intensity and change the vaporization signal according to the inhalation intensity.

[0119] The MCU 1501 may be configured to control the evaporator element 109 via an evaporation signal sent to an evaporator drive circuit 1512. The evaporator drive circuit 1512 may be minimally comprised of transistors configured to allow current to flow through the evaporator element 109 when activated by the MCU 1501. The evaporator drive signal may be “on / off” in nature, or may be varied using PWM to regulate the current flowing through the evaporator element 109.

[0120] Although the current does not have to be adjusted in order to vaporize the drawn medium, it is done to ensure complete vaporization without causing unwanted chemical changes that might be triggered by excessive heat. This can be accomplished using a temperature sensing circuit 1505 used in conjunction with, for example, a PWM vaporizer drive signal. The minimum temperature sensing circuit 1505 is Fig.15b 1528, gain resistors 1531 and 1532, and a voltage divider resistor 1529. The evaporator element 109 forms a voltage divider with the voltage divider resistor 1529. The voltage divider resistor 1529 is usually connected between the evaporator element 109 and the electrical ground 1530. Compared with the evaporator element 109, the voltage divider resistor 1529 usually has a low resistance value. This provides a small voltage difference across the voltage divider resistor 1529 without consuming too much energy required to evaporate the suction medium in the system. As the temperature of the evaporator element 109 changes, its resistance also changes. This change in resistance causes the small voltage difference across the voltage divider resistor 1529 to also change. The change is amplified by the operational amplifier 1528 according to a factor determined by the gain resistors 1531 and 1532. The resulting signal is provided by the sensing output 1527. The MCU can be configured to receive the sensing output 1527 and determine the temperature of the evaporator element 109 based on the analog level of the sensing output 1527. Informed by the sense output 1527 , the MCU 1501 may also be configured to adjust the evaporator drive signal in order to achieve a desired temperature at the evaporator element 109 .

[0121] The control circuit 120 may include a real-time clock 1504, which may be connected to the MCU 1501 to determine accurate time and date information. The MCU 1501 may be configured to store time and / or date information in the memory 1503. For example, when a user dispenses and inhales a dose, the time and / or date of the dose may be stored in the memory 1503. In addition, the MCU 1501 may communicate such stored information with a mobile application or a computer network using the above-mentioned communication interface circuit 1511. The MCU 1501 may also activate the vibration transducer 124 to signal the user the activation state of the vaporizer element 109 and / or the completion of the evaporation of the inhaled medium delivered to the vaporizer element 109. The MCU 1501 may be directly connected to the vibration transducer 124, or may be connected to a transistor that activates the vibration transducer 124. The vibration transducer 124 may be driven using an "on / off" drive signal or a PWM drive signal.

[0122] For example, the MCU 1501 may output a low duty cycle PWM signal that causes the vibration transducer 124 to vibrate softly during inhalation, and then output a high duty cycle PWM signal that causes the vibration transducer 124 to vibrate strongly to indicate when the dose has been completely vaporized. When used in conjunction with a touch-sensitive (with a touch-sensitive overlay) display screen 129, the vibration transducer may also be activated to provide tactile feedback in response to user input. When the user selects an element on the screen, the vibration transducer 124 may be activated for a period of time, typically less than 500ms, to coincide with the selection of the element and provide such tactile feedback.

[0123] The control circuit 120 may also include a battery charging control circuit 1510 that is responsible for managing the charging of the battery 111 when connected to a power source via the charging connector 103. The MCU 1501 may be configured to activate and deactivate the battery charging control circuit 1510. It may also be configured to receive information such as the state of charge from the battery charging control circuit 1510. The battery charging control circuit 1510 may include a temperature sensor, such as a thermistor, located near the battery 111 to determine the charging condition.

[0124] The control circuit 120 may also include an ambient temperature sensor 1509. The ambient temperature sensor 1509 may include a thermistor and a fixed resistor arranged in a voltage divider configuration. The MCU 1501 may be configured to receive analog signal information from a temperature sensor, and take certain actions based on temperature. For example, the MCU 1501 may be configured to prevent the control device 100 from operating when the ambient temperature is higher or lower than the rated operating conditions of its components. For example, the MCU 1501 may be configured to prevent the device 100 from operating when the ambient temperature exceeds the rated temperature of the battery 111. The MCU 1501 may also be configured to adjust operating parameters based on temperature conditions. The MCU 1501 may also be configured to regularly record temperature information and store it in the memory 1503 and / or the memory IC 205, or communicate with a computer or a computer network via a communication interface circuit 1511. The temperature information may be used to determine the user's behavior habits and predict, notify and / or compensate for changes or deterioration based on temperature of the suction medium.

[0125] The control circuit 120 may also include a voice recognition processor 1513 and a microphone 1515 for accepting verbal commands from a user. If the voice recognition processor 1513 and the microphone 1515 are combined, the MCU 1501 may be configured to accept input from the voice recognition processor 1513 for a variety of purposes, including but not limited to: setting a dose level, dispensing a dose, ejecting a storage box 200, initiating data transfer, connecting to a wireless network, changing device settings, and locking or unlocking the control device 100.

[0126] MCU 1501 can be configured to open and close indicator light 104a to 104d.It can also be configured to drive display screen 129.MCU 1501 can be configured to communicate with storage IC 205.MCU 1501 can read certain information from storage IC 205 for many purposes, and described purpose includes but is not limited to: determine the composition of inhalation medium, dosing, the amount of inhalation medium in storage box 200, evaporation parameter, determine the year of inhalation medium and display information about inhalation medium.MCU 1501 can also be configured to only enable control device 100 when having verified the security information from storage IC 205.For example, MCU 1501 can read serial number from storage IC 205, and compare it with the list of known serial numbers, to ensure that storage box 200 is not forged.Alternatively, MCU 1501 can be configured to read information from storage IC 205 and compare it with the format of expectation, to verify that storage box 200 is genuine. MCU 1501 can also be configured to implement a high-level security algorithm (e.g., SHA-256) in conjunction with the information stored in memory IC 205 to prevent the use of unauthorized cartridges 200. MCU 1501 can be configured to implement such security verification after connecting cartridge 200 or after one or more data exchanges between MCU 1501 and cartridge 200.

[0127] return Fig.15b, provides a detailed view of the evaporator drive circuit 1512 and the temperature sensing circuit 1505. The evaporator drive circuit 1512 may include an evaporator transistor 1526, which may typically be a field effect transistor (FET) having a current carrying capacity sufficient to supply current to the evaporator element 109. The evaporator transistor 1526 is configured to allow current to flow from the positive power supply 1524 to the power ground 1530 when commanded to do so by the MCU 1501. The MCU 1501 provides a PWM drive signal to the PWM input 1520 to activate the evaporator transistor 1526. In the current example, the circuit uses a PFET type evaporator transistor 1526, and may also include a pull-up resistor 1523, which is used to ensure that the evaporator transistor remains in the "off" state when the necessary PWM drive signal is not received. The circuit may also include an RC resistor 1521 and an RC capacitor 1522. These two components form a filter that keeps the transistor in the on state only when the PWM input oscillates within the required frequency range. In the event that MCU 1501 fails and generates an incorrect PWM drive signal, the inclusion of RC resistor 1521 and RC capacitor 1522 prevents evaporator transistor 1526 from remaining "on." Evaporator diode 1525 is provided to ensure that the voltage present on the gate of evaporator transistor 1526 does not temporarily exceed the allowed operating range when RC capacitor 1522 discharges and charges.

[0128] Fig.16a An example of the types of data elements that can be written to the memory IC 205 is shown. The memory can be formatted in such a way that each data element has its own size and address. For example, the device serial number indicating the serial number of the cartridge 200 can be 4 bytes in size and located at memory location 0001. For example, the media type indicating which type of media has been filled into a particular cartridge 200 can be 2 bytes and located at memory location 0010. The memory IC 205 can be used to store unchangeable data elements related to the cartridge 200 itself, such as the serial number, manufacturing date, and storage quantity of the cartridge 200.

[0129] The memory IC 205 may additionally be used to store immutable data elements related to the inhalation medium, including, but not limited to: fill date, expiration date, fill amount, optimal evaporation parameters, viscosity, density, default dosage, ingredients, chemical composition, genetic information, raw material information, grower information, weather conditions during the raw material growing process, raw material source information, testing laboratory digital certification, testing information, processing and production parameters, digital certification parameters, and the names of persons and / or entities associated with various stages of the production of the inhalation medium. Such immutable data elements may be programmed into the memory IC 205 when the cartridge 200 is manufactured, when the cartridge 200 is tested, or when the cartridge 200 is filled with the inhalation medium.

[0130] These constant data elements usually represent the inherent quality of each storage box, are usually not changed by the user or system, and can be write-protected to avoid accidental erasure or overwriting. Memory IC 205 can also include variable data elements, such as the number of suction events, the amount of remaining media, and the plunger position. When the product is used and the suction media is consumed, this type of variable data element can be updated with new data.

[0131] Memory IC 205 may also include unassigned data elements, such as parameter #1, parameter #2, and parameter #n. Such unassigned data elements are used to track additional information that may not be necessary to know during manufacturing or first use. Such data elements may also provide the user with the ability to customize the information tracked by the system. It should be understood that Fig.16a Only a limited number of examples of data elements that may be stored in memory IC 205 are shown.

[0132] Fig.16b 205. Fig.16a Any one or more of the data elements described in may be replicated in database 1600. In addition, Fig.16a Some of the data elements described in the above may preferably be stored in the database 1600 rather than in the memory IC 205. This may be advantageous for certain data elements, especially in situations where their formats may vary. For example, test information may come from multiple laboratories that report results in different formats. Rather than trying to store such information in the memory IC 205, it may be more practical to store it in the database 1600 and cross-reference one or more individual storage boxes 200 via data elements such as device serial numbers. The database 1600 may reside entirely on a single computer, have multiple complete copies distributed on multiple computers, or may be stored in fragments distributed between multiple computers.

[0133] It may be desirable to store certain information about the inhalation medium or cartridge 200 in a traceable manner that is difficult to forge or manipulate. For example, certificates of origin, test results, extraction process parameters, recipes, chemical identifiers, and genetic identifiers can all be information that would benefit from being stored in this manner. A blockchain system is one way to perform this task.

[0134] Fig.16b It is also shown how data elements from memory IC 205 can be stored in a blockchain arrangement within database 1600. Although some data elements from memory IC 205 can be stored within database 1600 but outside blockchain, one or more data elements from memory IC 205 can be used as content contained in blockchain. For example, device serial number data elements and other data elements can be used as content n of data block 1601a. ​​The device serial number is used as the input of the hash algorithm that creates hash n. This uniquely binds each storage box 200 to the blockchain through its unique device serial number located in memory IC 205, and makes it more difficult to forge storage box 200. In this way, the traceability of the inhaled medium stored in each storage box 200 is enhanced via the connection with the information that can be stored in data blocks 1601b and 1601c. Hash values ​​(such as hash n and hash n-1) can also be written to memory IC 205, thereby connecting digital security elements to physical products.

[0135] Fig.17a Device control scheme 1700 is shown, and this device control scheme describes how the vaporizer product 10 constructed according to the system and method described herein can distribute and evaporate multiple doses of inhalation medium.Device control scheme 1700 can be performed by a program or a plurality of functions programmed to be performed by MCU 1501.Device control scheme 1700 starts at frame 1701a.In frame 1701b, MCU 1501 can check regularly to see whether a new dose has been selected or whether a new dosing command has been received.This check can be initiated by MCU 1501 or by a system that provides updated input.If this happens, the new dose information will be read into memory 1503, otherwise, the pre-existing dose information will be retained in memory.In decision frame 1702, MCU 1501 determines whether there is enough inhalation medium left in storage box 200 to deliver the next dose.If the remaining inhalation medium is insufficient, then MCU will execute frame 1703, where the user is warned of the shortage. If there is sufficient inhaled material, the MCU proceeds to block 1704 where the drive signal required to dispense the desired dose is calculated.

[0136] In frame 1705, for example, by pressing dosing button 107a, it is indicated that the user needs this dosage. When this happens, MCU 1501 performs frame 1706 by transmitting the required driving signal of dispensing dosage, and this distribution is at most the maximum value that can be placed on evaporator element 109 at any time. Some inhalation media may have high viscosity, and may not evenly cover the surface of evaporator element 109. In order to diffuse inhalation media, MCU can perform optional frame 1707 by energizing evaporator element 109 in a short time or with low power level, so that the inhalation media is heated gently to reduce its viscosity and cause the diffusion of inhalation media. After dispensing dosage, frame 1708 is performed by providing visual, audible or tactile indication to the user.Depending on the surface tension and viscosity of inhalation media and the distance between storage box outlet 202 and evaporator element 109, a small amount of inhalation media can remain suspended at the lead-out end of storage box outlet 202. To prevent accidental evaporation and / or leakage of suction medium, optional block 1709 may be performed by retracting dispense motor 112 slightly to draw any such suction medium away from evaporator element 109. Doing so may also relieve any residual pressure in suction medium storage area 206, thereby reducing the tendency for suction medium to leak.

[0137] At box 1710, the user begins to inhale, which generates a signal output or signal output change at the inhalation sensor 119, as shown in box 1711. After detecting this inhalation, box 1712 is executed. Box 1712 (i.e., the evaporator control loop) is responsible for energizing and controlling the temperature of the evaporator element 109, and will be described in further detail below. When the user inhales, optional box 1713 can be executed. In box 1713, the vibration transducer 124 can be turned on or off in different modes at a specific level to indicate that the inhaled medium is evaporating. For example, a specific level can cause a vibration of a low intensity level, which is perceptible but does not destroy or distract the inhalation experience. Once the user stops inhaling, as shown in box 1714, box 1715 is executed by terminating the evaporator control loop 1712. If optional box 1713 is executed, it can be terminated in optional box 1716.

[0138] In frame 1717, memory IC 205 can be updated to reflect up-to-date consumption information.For example, the quantity of the suction event can increase by one, to reflect the suction event just terminated.Other examples of the information that can be updated can include but not limited to the position of plunger driver 116, the duration of the recent suction event, the total duration of all suction events of given storage box 200, the time of the recent suction, the volume of the recent suction, the speed of the recent suction and the amount of the suction medium remaining in the storage box 200.The copy of such above-mentioned information also can be updated in memory 1503 and / or be sent to computing device 1803 and / or database 1600.

[0139] In decision block 1718, MCU 1501 determines whether the dose has been completely vaporized. This determination can be based on a known relationship between the duration of inhalation and the vaporization rate or other methods involving temperature, power and / or current monitoring described below. If the dose has been completely vaporized, optional block 1719 can be executed by using the vibration transducer 124 to generate a unique vibration pattern. Examples of such patterns include a single strong pulse and a series of discrete pulses. At this point, the device control scheme 1700 can be terminated at block 1720, at which time, the MCU can perform other tasks and / or restart at block 1701a. If the result of decision block 1718 is negative, block 1721 can be triggered to indicate to the user that the dose has not been completely vaporized. The indication can be auditory, visual or tactile, thereby utilizing various indication components present in the control device 200. For example, a message can be displayed on the display screen 129 to inform the user that the dose has not been completely vaporized. After such an indication, in block 1722, the MCU waits until the user starts a new inhalation in block 1710. This process can be repeated until the entire dose is vaporized.

[0140] Fig.17b An exemplary embodiment of block 1712 is described. In this embodiment, the time-based vaporization control loop 1712a involves using the relationship between vaporization duration, temperature, and vaporization rate to determine when the vaporized medium is completely vaporized. For example, it may be determined through testing that 1 unit mass of a particular inhalation medium formulation at a given temperature requires 1 unit of time to completely vaporize. This relationship can be expressed as the formula R 温度 ×Time 蒸发 =Quality 已蒸发 To indicate. 温度 The value of may be unique for each inhalation medium and may be stored in the memory IC 205, the memory 1503, the computing device 1803 and / or the database 1600. The time-based vaporization control loop 1712a begins at block 1723. In decision block 1724, the MCU 1501 checks to see whether the dose to be vaporized during the current inhalation is a new dose or a continuation of a previous dose that has been partially dispensed and / or partially vaporized. This may be accomplished by checking the value of a countdown timer and / or the value of a continuous state variable stored in any one of the memory IC 205, the memory 1503 and the database 1600.

[0141] If the dose to be vaporized during the current inhalation is a new dose, then block 1725 is executed. In order to calculate the time to vaporize the required dose, the MCU 1501 can read the necessary constant R 温度 And perform the calculation of mass 已蒸发 / R 温度 =Time蒸发 .time 蒸发 Can be represented by many timer count values. In alternative embodiments, the time corresponding to the possible dose at a given temperature can be represented by 蒸发 A table or list of values ​​is stored in the database 1600 and retrieved by the MCU 1501, however, the R for a given inhaled medium 温度 Storing values ​​in the memory IC 205 and performing calculations on the MCU 1501 allows the control device 200 to function without being connected to a network.

[0142] In block 1726, the countdown timer is set to the number of counts determined in block 1725. In block 1727, the evaporator element 109 is powered on and maintained at the desired temperature using the temperature feedback loop. In block 1728, the countdown timer is decremented, and in decision block 1729, the countdown timer is evaluated to determine whether it is greater than zero. If the countdown timer is greater than zero, decision block 1730 is executed to determine whether the entire requested dose has been dispensed. If the dose requested by the user is greater than the dose that can be placed on the evaporator element 109 at a given time, a dose that is less than the requested dose will be placed on the evaporator element 109 first. The amount initially placed can be recorded in the memory 1503 and / or the memory IC 205 and compared to the requested amount. This comparison is done in decision block 1730. If the requested dose has been fully dispensed, the program loops to block 1727. If the requested dose has not been fully dispensed, the MCU 1501 may drive the dispensing motor 112 to dispense an incremental amount of inhaled medium onto the vaporizer element 109 before looping to block 1727. The MCU 1501 may loop through the above process until the countdown timer value reaches zero. At this point, block 1732 is executed by deactivating the vaporizer element 109 and the process is terminated in block 1733.

[0143] It should be noted that, according to the device control scheme 1700, the cycle through the time-based vaporization control loop 1712a may also be interrupted by terminating the user's inhalation. If this occurs before reaching block 1733, the most recent value stored in the countdown timer is saved, and the continuous state variable may also be set in the memory IC 205 and / or the memory 1503. At the next initiation of the time-based vaporization control loop 1712a, the result of decision block 1724 will continue directly to block 1727 because the value of the countdown timer is greater than zero and / or because the continuous state variable is set to indicate continuation.

[0144] Fig.17cAn alternative embodiment of block 1712 is described. A temperature-based evaporation control loop 1712b involves setting the power delivered to the evaporator element 109 to a given level and monitoring the temperature. A temperature control curve 1740 represents the temperature of the evaporator element 109 for a given power level. When the evaporator element 109 is initially energized, the temperature rises rapidly in a temperature preheating region 1741 as energy flowing from the evaporator element 109 increases the temperature of the suction medium. When the suction medium reaches its evaporation temperature, the energy from the evaporator element 109 causes a phase change in the suction medium, thereby producing suction vapor that begins approximately at a temperature evaporation threshold 1742. As evaporation occurs, the temperature stabilizes in a temperature stabilization region 1743. When the suction medium is exhausted (completely or nearly completely evaporated from the evaporator element 109) at a medium exhaustion time 1744, energy from the evaporator element 109 no longer flows into the suction medium, and the temperature of the evaporator element 109 begins to rise rapidly in a temperature exhaustion region 1745.

[0145] MCU 1501 can be configured to identify the characteristics of the above-mentioned area. When reaching the temperature exhaustion zone 1745, MCU 1501 can be configured to detect the temperature rise that exceeds the temperature limit 1746, make the evaporator element power off and terminate the evaporation control loop 1712b based on temperature. Temperature limit 1746 can be a unique value for each inhalation medium preparation, and can be stored in memory IC 205, memory 1503, computing device 1803 and / or database 1600. Alternatively, temperature limit 1746 can be set to a percentage higher than the temperature stabilization zone 1743. MCU 1501 can also be configured to calculate the temperature rise rate 1747, to determine when the inhalation medium is exhausted. The reason why this method is feasible is that the temperature change rate during the temperature exhaustion zone 1745 can be significantly different from the temperature change rate of the temperature stabilization zone 1743.

[0146] Similar to blocks 1730 and 1731 of the time-based vaporization control loop 1712a, the temperature-based vaporization control loop 1712b may include dispensing of additional replenishment of inhalation medium during inhalation, if necessary, such as to provide a larger dose than initially dispensed onto the vaporizer element 109. Preferably, this will be done during the temperature stabilization region 1743. Also similar to the time-based vaporization control loop 1712a, the temperature-based vaporization control loop 1712b may be interrupted by termination of inhalation by the user.

[0147] Fig.17dAnother exemplary embodiment of block 1712 is described. A power-based evaporation control loop 1712c involves setting the temperature delivered to the evaporator element 109 to a given level and monitoring the power required to maintain that temperature. A power control curve 1750 represents the power delivered to the evaporator element 109 to maintain it at the set temperature. When the evaporator element 109 is initially energized, the power required to reach the desired temperature rapidly decreases in a power start region 1751 as energy flowing from the evaporator element 109 increases the temperature of the intake medium. When the intake medium reaches its evaporation temperature, the energy from the evaporator element 109 causes the intake medium to undergo a phase change, thereby producing intake vapor at approximately a power evaporation threshold 1752.

[0148] As evaporation occurs, the power required to maintain the desired temperature stabilizes in power stabilization region 1753. When the suction medium is depleted at power medium depletion time 1754, energy from the evaporator element 109 no longer flows into the suction medium, and the power delivered to the evaporator element 109 begins to decrease rapidly in power depletion region 1755.

[0149] MCU 1501 can be configured to identify the characteristics of the above-mentioned area. When arriving at power exhaustion area 1755, MCU1501 can be configured to detect the power reduced to below power limit 1756, disconnect the evaporator element and terminate the evaporation control loop 1712c based on power. Power limit 1756 can be a unique value for each inhalation medium preparation, and can be stored in memory IC 205, memory 1503, computing device 1803 and / or database 1600. Alternatively, power limit 1756 can be set to a percentage lower than power stable area 1753. MCU 1501 can also be configured to calculate power reduction rate 1757, to determine when inhalation medium is exhausted. The reason why this method is feasible is that the power change rate during power exhaustion area 1755 can be significantly different from the power change rate of power stable area 1753.

[0150] Similar to blocks 1730 and 1731 of the time-based vaporization control loop 1712a, the power-based vaporization control loop 1712c may include dispensing of additional replenishment of inhaled medium during inhalation, if necessary, such as to provide a larger dose than initially dispensed onto the vaporizer element 109. Preferably, this will be done during the power stabilization region 1753. Also similar to the time-based vaporization control loop 1712a, the power-based vaporization control loop 1712c may be interrupted by termination of inhalation by the user.

[0151] Fig.18Described dosing network system 1800, this dosing network system can comprise control device 100, storage box 200, computing device 1803 and computer network 1801.The data element relevant with characteristic, storage box 200 and / or its manufacturing of inhalation medium can be exchanged between control device 100 and storage box 200.The data element stored in storage box 200 can also be uploaded to the database 1600 that is arranged in computer network 1801 at any time during the manufacture, filling or use of storage box 200.Can finish uploading this type of data element in manufacturing or filling process via control device 100 or via the manufacturing fixture (not shown) that is designed to dock with memory IC 205 and computer network 1801.Upload data element immediately after manufacturing and / or filling and can create the record of the inhalation medium that storage box 200 is associated, and this may be of benefit to the management and tracking of inventory and anti-counterfeiting and verification measures.

[0152] Data elements related to product consumption (including but not limited to: dosage event time, dosage event duration, dosage quantity, dosage nature and remaining inhalation medium amount) are usually generated or updated by the control device 100. Although such data elements related to consumption can also be stored in the memory IC 205, the memory 1503 and / or the computing device 1803, they are usually uploaded to the database 1600 via the first communication link between the control device 100 and the computing device 1803, and the computing device is linked to the computer network 1801 via the second communication link. The second communication link can usually be a digital cellular, Zigbee or Wi-Fi connection. In other embodiments, the control device 100 may include circuits necessary for communicating directly with the computer network 1801.

[0153] The data element relevant to consumption can be uploaded to database 1600 after each triggering event (usually suction) or in batches. Computing device 1803 can have feedback application 1804, and this feedback application is configured to display communication and accepts the feedback from the effect of the inhalation medium dosage of the user. Feedback application 1804 can be configured to accept the background information from the user in addition, including but not limited to the reason of age, weight, sex, physical condition and user consumption inhalation medium. Feedback application 1804 can be the computer application that resides on computing device 1803, or can be the remote interface of the application program that performs in computer network 1801. Communication, feedback and the information that provide via computing device 1803 can be provided by component display enabling control device 2100 or connection accessory (such as smart watch 1806) alternatively or additionally.

[0154] Computer network 1801 may include chat agent 1802, which is configured to solicit feedback from the user and store the feedback in database 1600. Chat agent 1802 may also be configured to solicit background information from the user. Feedback may be solicited at any time, however, soliciting such feedback in response to dosing events may be particularly useful. For example, if it is expected that the pain relief effect of a specific inhalation medium will be felt after dosing in 10 minutes, chat agent 1802 may be configured to send communication to the user after dosing events occur and / or are received in database 1600 in 10 minutes. Chat agent 1802 may ask a series of questions to the user, and may customize its problem according to the answer given by the user. For example, chat agent 1802 may require the user to rate the pain relief provided by a certain dose of a specific inhalation medium with a digital magnitude, and a higher value provides a higher degree of pain relief. If the user responds with a low numerical value, chat agent 1802 may ask the user why they think that the pain relief value is low. As a further example, if there are unusual patterns in dosing behavior and / or there are extended periods where no dosing has occurred, the chat agent 1802 may also solicit feedback. For example, if the user stops consuming an inhaled medium intended to provide pain relief, it may indicate that the underlying condition causing the pain has been resolved. The chat agent 1802 may ask questions about the underlying condition.

[0155] Computer network 1801 can also include data analysis program 1805, which is configured to analyze the information stored in the database and determine the optimal dose, frequency, timing, type and other properties for a given user. Such dosing information can be provided to the user via chat agent 1802. Data analysis program 1805 can be configured to monitor user consumption in addition and provide additional type of feedback. For example, data analysis program 1805 can determine that the data element associated with plunger driver 116 indicates that most of the suction medium in the storage box 200 has been consumed, and can trigger chat agent 1802 to send communication to the user, to warn them of this situation, and provide the user with the information about how to buy other storage box 200, for the information of the coupon of other storage box 200, or even the user is linked to the digital order fulfillment system to buy the information of other storage box 200. Data analysis program 1805 can be configured to initiate other types of communication with the user in addition, including but not limited to: promotion, discount, educational information, inventory level, new product introduction, validity period and recall information. While providing such dosing and other types of communications to the user via the chat agent 1802 provides an easy to understand interface to the user, there are alternative embodiments where such information is sent to the computing device 1803 and displayed by an application that is not a chat-type application or interface.

[0156] Fig.19 Shown is a dose recording process 1900, which can be used to capture dosing information and store it in a database 1600. The dose recording process 1900 starts at box 1901. When the user selects and dispenses the desired dose in box 1902, the dosing information including the dose is stored in memory 1503 in box 1903. In box 1904, MCU 1501 can be additionally configured to read certain data elements from memory IC 205 and store them in memory 1503. In this way, memory 1503 has a complete record of the dose to be inhaled. When the user starts inhaling in box 1905, in box 1906, MCU 1501 starts a clock timer until the user completes inhalation in box 1907, and the clock timer stops in box 1908. MCU 1501 can be configured to use an internal timer as a clock timer, or can be configured to use an external clock (such as real-time clock 1504) to provide accurate time information. Next, the duration of the inhalation can be calculated in box 1909 by subtracting the clock timer start value from the clock timer end value. In box 1910, the inhalation duration and other dynamic information can be written to the memory 1503. Such dynamic information can include, but is not limited to, the time of day of inhalation, the intensity of inhalation, the ambient temperature, the temperature of the evaporator element 109 during inhalation, and the intensity of inhalation. At this point, the memory 1503 now contains an inhalation record that includes the inherent characteristics of the inhalation medium and the dynamic characteristics of a single inhalation event. Such information can be combined into a single data structure in box 1911 and then sent to the computing device 1803 in box 1912. Alternatively, such information can be sent directly to the computing device 1803 in sections.

[0157] Once the record is stored in the computing device 1803, additional information can be added to the record in box 1913. Such additional information can include information known to the computing device 1803 but unknown to the control device 100. Such additional information can include, but is not limited to, GPS coordinates, weather conditions, account information, recent medications, mood, heart rate, blood pressure, body movement, breathing rate, blood oxygen level, ECG, EKG, and other biometric information available to the computing device 1803. Some of this additional information can be provided to the computing device 1803 via a connected accessory such as a smart watch 1806, a heart rate monitor, an ECG monitor, or a blood pressure monitor. The data record can now include information from the storage box 200, the control device 100, and the computing device 1803. In box 1914, the complete data record can be uploaded to the database 1600. In box 1915, in the process of storing the record in the database, the record can be associated with the user. One way of association can be done via a user account name or account number. Once the record has been associated with the user, the computer network 1801 can optionally be configured to send a message to the user via the computing device 1803 indicating that the most recent dose has been recorded, thereby ending the process at box 1917. It is not necessary to perform a step-by-step assembly of the data record. Instead, the data elements can be uploaded to the database 1600 separately as they become available and then associated at the database 1600 level. In further alternative embodiments, the control device 100 can communicate directly with the computer network 1801 and may not necessarily include information provided by the computing device 1803.

[0158] Fig. 20The dosage recommendation process 2000 is shown, and the dosage network system 1800 can determine the dosage suggestion and provide it to the user through the dosage recommendation process. The dosage recommendation process 2000 can contain information related to multiple users. Each user can be distinguished by a unique account, name or other form of unique identifier. For the purpose of this specification, "user n" refers to a specific user defined by its unique identifier "n", where n is a unique number associated with the user. The process starts at box 2001. In box 2002, user n enters background information into the database 1600 via feedback application 1804, other applications on computing device 1803, control device 100, in-line component control device 3501 or component display enabling control device 2100. Such background information can include characteristics of user n and other information related to determining the optimal dosage parameters of inhaled medium. Such background information can include, but is not limited to: age, weight, sex, physical condition including disease, mental condition and disease of the user, previous consumption of other inhaled media, medicine and drug use, and reasons for the user to consume inhaled media. User n may provide and update such information at any time, however, it is preferred that such information be provided prior to initial use.

[0159] In frame 2003, after such information is provided, user n consumes inhalation medium. In frame 2004, in response to inhalation, the dosing information of user n can be uploaded to database 1600. Frames 2003 and 2004 can be performed together according to dosage recording process 1900. In frame 2005, after inhalation, chat agent 1802 asks user n for feedback on the effect of the relevant dosage. The type of effect feedback requested can include but is not limited to the rating of pain relief, the rating of the effect of physical disease or condition, mood changes, mood changes, anxiety level, appetite changes and side effects. Chat agent 1802 can also ask for other relevant feedback at this time, including but not limited to: other medicines taken recently, recent noteworthy events and recent food and beverage consumption. In frame 2006, such feedback from user n is stored in database 1600. It should be noted that although frames 2002 to 2006 can occur in a sequential manner, some frames can also be skipped in some cases. For example, user n may execute block 2002 and then jump directly to the dosage recommendation in block 2019 before executing block 2003 . Fig. 20 Dashed lines in indicate situations where the user can skip to a different step in the process.

[0160] The data elements and feedback stored in the database 1600 can be labeled and grouped in this way to facilitate data analysis. For example, the database 1600 may include a global background set 2010, which is a collection of background information from all users of the system, including background records 2007 for user n. The database 1600 may also include a global dose set 2011, which is a collection of dosing information from all users of the system, including dosing information records 2008 for user n. The database 1600 may also include a global effect set 2012, which is a collection of effect information reported by all users of the system, including effect records 2009 for user n. The data analysis program 1805 may be configured to analyze the global background set 2010, the global dose set 2011, and the global effect set 2012 to extrapolate patterns and / or find correlations. Such extrapolation or correlation can be used to identify optimal dose information for user n. Modern data mining techniques provide many methods for performing such extrapolations, including but not limited to: tracking patterns, classification, association, outlier detection, clustering, regression, and prediction. Data analysis program 1805 may employ one or more of these techniques to identify the optimal dose for user n.

[0161] Fig. 20 An exemplary simplified method is shown in . Background function 2015 can be a function that compares the background record 2007 of user n with all users in the global background set 2010 to determine which users are most similar to user n. It can assign a value to each user based on the similarity of each user to user n. Global function 2016 can be a function that receives data from the global dose set 2011 and the global effect set 2012 and determines which doses have the greatest effect on the entire user group. User n function 2017 can be a function that receives data from the dosing information record 2008 of user n and the effect record 2009 of user n and determines which doses have the greatest effect on user n.

[0162] The output of background function 2015, global function 2016 and user n function 2017 can be received by recommendation function 2018. Recommendation function can be configured to determine which doses have the greatest effect on the user most similar to user n, and compare it with the most effective dose consumed by user n. If the dose of similar users has a greater effect than the dose consumed by user n, recommendation function 2018 can suggest that user n try a dose that has a greater effect on similar users. Data analysis program 1805 can also be configured to extrapolate other patterns or find other correlations, including but not limited to: drug interactions, side effects, tolerance enhancement, adaptability, treatment of diseases, improvement of physical or mental conditions, and food interactions. Data analysis program 1805 can adjust recommendations in response to this pattern. For example, it may be noted that users tend to develop tolerance to certain inhaled media, and recommendations can be adjusted to compensate accordingly.

[0163] After the recommendation function 2018 generates a recommendation, in box 2020, the recommendation can be communicated to the user. This can be communicated via the feedback application 1804 or some other application executed on the computing device 1803, the control device 100, the in-line composition control device 3501, or the composition display enabling control device 2100. It should also be noted that in box 2019, this communication can be in response to a dose matching request by user n. Alternatively, the data analysis program 1805 can be configured to trigger this communication whenever a dose that produces a greater effect on a user similar to user n is identified. The dose recommendation process 2000 terminates at box 2021. It should also be noted that the dose recommendation process can be a permanent process, in which additional data is continuously added to the database 1600 via one or more users, analysis is continuously performed, and recommendations are continuously made.

[0164] Fig.21aShow composition and display and enable control device 2100, it is the embodiment of control device 100, and this control device comprises the display screen 129 that is configured to show the composition of the inhalation medium contained in storage box 200.Display screen 129 can show title 2101, and this title provides general description and / or the name of the inhalation medium contained in storage box 200.Display screen 129 can also be configured to show one or more key components 2102a to 2102n of inhalation medium.Key components can include but are not limited to nicotine, flavonoid, terpene, terpenoid, medicine, drug, active ingredient, preservative, solvent and carrier material.Display screen 129 can also be configured to show and enable the additional information of control device 2100 about inhalation medium, storage box 200 and / or composition display.Control panel 130 can be used for navigation and displayed information, so that check other compositions that are not shown on display screen 129. The control panel 130 may be further configured to select an ingredient to enable the control device 2100 to indicate to the ingredient display the ingredient that the user desires to dose and the amount of the ingredient that the user wants to consume.

[0165] Figure 21b A dose visualization application 2103 is shown, which is configured to communicate with the control device 100, the in-line ingredient control device 3501, or the ingredient display-enabled control device 2100, and displays the composition of the inhalation medium in the cartridge 200. The dose visualization application 2103 can be configured to run on the computing device 1803. The dose visualization application 2103 can be additionally configured to display an application title 2104 and an ingredient list 2105. The user can navigate the ingredient list using controls provided by the computing device 1803. The dose visualization application 2103 can be additionally configured to allow the user to select the ingredient that the user desires to be dosed and the amount of the ingredient that the user wishes to consume in the dose. The dose visualization application can be additionally configured to display other information related to the inhalation medium, including, but not limited to: date of manufacture, expiration date, origin information, producer information, production process information, testing information, efficacy, and proof of authenticity.

[0166] Fig.21c The ingredient dosing process 2110 is shown starting from box 2111. In box 2112, the user selects the ingredient to be dosed, and in box 2114, the amount of the ingredient to be dosed. Such selection can be made via the ingredient display enabled control device 2100, the inline ingredient control device 3501, or a dose visualization application 2103 in communication with the control device 100, the ingredient display enabled control device 2100, or the inline ingredient control device 3501. In box 2113, the percentage composition of the selected ingredient and other key ingredients is read into the memory 1503. In box 2115, the total amount of inhalation medium dispensed to deliver the requested dose of the target ingredient is calculated by the MCU 1501.

[0167] The mathematical formula for calculation can be expressed as (the mass percentage of the requested composition present in the dosage of the requested composition ÷ the inhalation medium = the total amount of the inhalation medium to be delivered). For example, if the user requests a 5mg CBD dosage from a cartridge 200, and the cartridge contains an inhalation medium with a CBD composition of 25% by mass, the calculation result can be 20mg total inhalation medium. In decision block 2116, MCU 1501 reads memory IC 205 and determines whether enough inhalation medium remains to deliver the requested dosage. Continuing the example from above, cartridge 200 will need to accommodate at least 20mg of inhalation medium.

[0168] If there is not enough inhalation medium remaining, this condition is communicated to the user in box 2123, and in decision box 2124, the user is given the choice of continuing and dispensing a partial dose or aborting the dose request and restarting the process. If there is enough inhalation medium to deliver the requested dose, or if the user chooses to receive a partial dose, the amount of other key ingredients to be delivered is calculated in box 2117 and communicated to the user. Continuing with the example above, if the inhalation medium contains 1% pinene, and pinene has been selected as the target ingredient, the control device 100 can communicate to the user that 0.20 mg of pinene will be delivered in the dose. The ingredients of interest can be determined by the user, or can be automatically retrieved from a list stored in the database 1600 or the computing device 1803. For example, ingredients that are known to be toxic above a certain amount can be included in the list of ingredients of interest.

[0169] In decision block 2118, MCU 1501 may be configured to compare the amount of one or more components in the requested dose to the limits. A list of dose component limits may be stored in memory 1503, memory IC 205, computing device 1803, or database 1600, where MCU 1501 may access such limit information via the aforementioned communication link. Such limits may be set by a user, a third party, or determined by data analysis program 1805. If such limits are exceeded, the condition is communicated to the user in block 2119, and the user may choose to abort the requested dose and restart or continue the dose in decision block 2120.

[0170] Continuing the above example, if the dose limit of pinene has been set to 0.10 mg, the user may be notified of this condition in box 2119. If the user selects to continue the dose in decision box 2120, or the limit is not exceeded in box 2118, the control device 100, the inline component control device 3501, or the component display enables the control device 2100 to dispense the dose in box 2121, and then complete the process in box 2122. Completing the above example, 20 mg of inhalation medium will be dispensed for the user to inhale. It should be noted that by knowing the density of the inhalation medium and the mass percentage of the component composition (which can be stored in the memory IC 205, the memory 1503, the computing device 1803, and / or the database 1600), the MCU can calculate the volume of the inhalation medium to be dispensed for delivering the requested dose.

[0171] In component display, enable control device 2100, in-line component control device 3501 or control device 100, there is no need to calculate the amount of component, check enough inhalation medium and compare with component dosage limit. These actions can be performed by the application program located on computing device 1803 or computer network 1801. In such an embodiment, the final dose to be distributed can be communicated to component display, enable control device 2100, in-line component control device 3501 or control device 100. It should be further noted that in component display, enable control device 2100, in-line component control device 3501 or control device 100 to be configured to receive and distribute the inhalation medium from a plurality of storage boxes 200 connected simultaneously, the amount of the inhalation medium distributed from each storage box 200 can be determined respectively, so as to provide the user with the closest matching of the dosage component distribution requested by the user. For example, it can be determined that 7mg should be distributed from the first storage box 200, and 3mg is distributed from the second storage box 200, so as to produce the 10mg dosage with the desired component composition.

[0172] The composition of the inhalation medium may change over time due to a variety of factors including, but not limited to, exposure to heat, radiation, moisture, ultraviolet light, oxygen, and chemical reactions with other ingredients. Fig.22aOne aspect of a dose visualization application 2103 is shown, which is configured to display such changes in the effectiveness or composition of the inhalation medium in the cartridge 200 and compensate the dose to account for such changes. The dose visualization application 2103 may include a composition change indicator 2201, which provides a user with a visual representation of the degree of change since a particular component or a group of components were manufactured, tested and / or filled into the cartridge 200. The dose visualization application 2103 may also include a compensation selector 2202, which will cause the control device 100, the component display enabling control device 2100, or the inline component control device 3501 to distribute the compensated dose. For example, if a user wants to consume a 1 mg dose of nicotine from an inhalation medium that originally contains 5% by mass of nicotine, but determines that the percentage of nicotine in the inhalation medium has decreased by 50%, a total dose of 40 mg will be distributed to enable the user to receive the required 1 mg of nicotine.

[0173] Figure 22b A dose compensation process 2210 is shown for adjusting the dose to compensate for composition changes. The process begins at box 2211. In box 2212, the user enters the desired ingredient for dosing and the amount of that ingredient he requires, i.e., the dose target. As described above, the control circuit including a processor (e.g., the control circuit 120, which may include the MCU 1501) will then determine the dose of inhaled medium required to deliver the dose target. However, in Figure 22b During the process, the user selects whether to use dosage compensation in decision box 2213. If the user does not select, the uncompensated inhalation medium dose is delivered in box 2219, and then the process is completed in box 2218.

[0174] On the other hand, if the user requests dosage compensation, the control circuit can query one or more compensation values, such as stored in the memory, for one or more compensation categories to determine the appropriate compensation for the inhaled medium dosage to ensure that the dosage target is reached. For example, if the compensation category is year, then in frame 2114, the production date, test date or year of the inhaled medium can be read from the memory IC 205, the memory 1503, the computing device 1803 or the database 1600. In frame 2215, the compensation factor (such as the compensation factor can be 1.5) associated with the year of the selected component in its current year is retrieved from the memory IC 205, the memory 1503, the computing device 1803 or the database 1600, in this case, the compensation value, any one of the memory IC, the memory, the computing device or the database can include a list of compensation factors for one or more components of multiple years. The retrieved compensation factor is then applied to the dosage calculation.

[0175] In box 2217, the compensated dose of inhaled medium is dispensed and the process ends at box 2218.

[0176] The dose compensation process 2210 may be executed on the control device 100, the component display enabling control device 2100, the inline component control device 3501, the computing device 1803, the computer network 1801, or distributed in any one or more of these elements. The dose compensation process 2210 may also be combined with other processes such as the component dosing process 2110.

[0177] Alternatively or in combination, the dose compensation process 2210 may use an equation rather than a stored list of compensation factors to adjust the dose. For example, if the variation of one or more components follows a first order equation, the compensation factor for a given component may be calculated as: Compensation Factor = 1 ÷ e -kt ; where e = base of natural logarithm, k = rate constant, and t = time. Each component may have its own unique rate constant k, in this case a compensation value, which may be stored in one or more of memory IC205, memory 1503, computing device 1803, or database 1600 and retrieved to perform the calculations.

[0178] It is desirable not only to know how much the first component has increased or decreased, but also how much the other components have changed due to the change in the first component. Therefore, the conversion rate from the first component to the second component can be characterized and captured in an equation or compensation factor so that the dosage of the second component can be compensated according to the same process described above. As described above, the conversion rate may be affected by external conditions (e.g., compensation categories, such as temperature).

[0179] In another alternative embodiment, the dose compensation process 2210 can obtain additional input from any one of the ambient temperature sensor 1509, the temperature sensor and data logger built into the storage box 200, the oxygen sensor, the humidity sensor, the UV light sensor, the radiation sensor, or other environmental sensors. Using this environmental information, a more accurate compensation factor or rate constant, i.e., compensation value, can be selected for use in the dose compensation calculation. In other words, compensation values ​​for multiple compensation categories (e.g., temperature, oxygen level, humidity, UV light exposure, radiation exposure, etc.) can be determined and stored for use in determining the inhaled medium dose compensation.

[0180] It should also be understood that some compositions may increase over time. In some cases, when a user requests a certain dose of the first composition, the amount of one or more other compositions in the dosage calculated after applying the dosage compensation process 2210 may exceed a threshold value. Therefore, the list of dosage composition threshold values ​​may also be stored in the memory 1503, the memory IC 205, the computing device 1803 or the database 1600. For example, the threshold value may be relevant with the composition toxicity of the level identified by pharmacological studies. The dosage compensation process 2210 may be configured to automatically calculate the amount of other compositions present in the inhaled medium dosage, if such amount exceeds any threshold value, then notify the user, and provide a series of actions to be taken to the user, such as suspending the dosage or adjusting the inhaled medium dosage.

[0181] Fig.23A remote dosing process 2300 is shown, in which dosing can be controlled by a third party. Examples of third parties include, but are not limited to, doctors, health care providers, nutritionists, consultants, and virtual agents, including data analysis programs 1805. Potential benefits of remote control dosing include enabling a third party to monitor the effects of dosing and adjust dosing accordingly, improving compliance with the correct dosing schedule, and ensuring that the correct amount of inhaled medium is consumed, thereby reducing the possibility of underdosing and overdosing. Data collected by professionals monitoring remote control dosing can be used as training data to train a machine learning system to perform a dose recommendation function. Remote dosing process 2300 starts at box 2301. In box 2302, a user selects third-party control. Such a selection can be performed via a dose visualization application 2103 configured to communicate with control device 100, inline component control device 3501, or component display enabling control device 2100, or can be performed directly via a built-in interface of control device 100, inline component control device 3501, or component display enabling control device 2100. Alternative embodiments of the control device 100, the inline component control device 350, and the component display enabling control device 2100 can be preconfigured to function only via remote dosing. In box 2303, the third party enters the dosing information into the database 1600. In box 2304, when dosing is required, the application running on the computer network 1801 can issue a reminder to the user. Such reminders can usually be displayed on the computing device 1803, but they can also be displayed on the inline component control device 3501 and the component display enabling control device 2100. In box 2306, the user can optionally check the reminder and dosing information via an application running on the computing device 1803 (such as a dose visualization application 2103). In box 2305, when the user attempts to dose, in box 2308, the control device 100, the component display enabling control device 2100, or the inline component control device 3501 can download the latest dosing information from the database 1600. Optionally, a copy of such dosing information may be downloaded to any of the control device 100, the ingredient display enabled control device 2100, the inline ingredient control device 3501, or the computing device 1803 at regular intervals in advance to enable dosing when a connection to the computer network 1801 is unavailable. In block 2309, the dose is dispensed and vaporized according to the process previously described in this document. In block 2310, once the dose has been vaporized, information about the consumption of the dose may be recorded in the database 1600. In block 2313, if the control device 100, the ingredient display enabled control device 2100, or the inline ingredient control device 3501 also maintains a local copy of the dosing scheme, information about the consumption of the dose may also be recorded in a memory in the control device 100, the ingredient display control device 2100, or the inline ingredient control device 3501.Optionally, after the dose has been recorded in block 2310, an application running on computer network 1801 may generate a notification to a third party in block 2312. Such a notification may indicate that the dose has been consumed and / or certain characteristics about the dose, such as the time at which the dose was consumed. The process ends in block 2311.

[0182] It should be noted that remote dosing process 2300 can be used not only by a third party, but also by the user himself. For example, the user may worry that he may be subject to temporary cognitive impairment of a certain inhaled medium in his dosing scheme, and may not make the right decision once he starts to consume dosage. In this case, the user may wish to set up his own dosing schedule in database 1600 when not subject to cognitive impairment. Since the system has the ability to limit the dose delivery according to the schedule provided in database 1600, the user will not be able to exceed the dosing limit when subject to cognitive impairment. A third party and / or user can also include a lockout time in the dosing schedule to prevent delivery of dosage at certain times of the day, a few days of the week, or within a certain time range since the most recent dose.

[0183] Fig.24a and Figure 24bA passive vaporizer article 2400 including a passive control device 2401 and a passive inhalation medium storage box 2410 is described. The passive vaporizer article 2400 may be generally referred to as an ecig, and is the basic design used by well-known products, including but not limited to: blu ecigs plus+, blu ecigs my blu, RJ Reynolds Vuse and JUUL. The passive inhalation medium storage box 2410 also includes a passive storage box housing 2412 and an internal air tube 2414 located within the passive storage box housing 2412. The space between the passive storage box housing 2412 and the internal air tube 2414 forms a passive inhalation medium storage area 2413 for storing inhalation medium. The passive storage box housing 2412 may be a circular tube, such as blu ecigs plus+, or may have a non-circular cross-section, such as JUUL. The internal air tube 2414 may be a circular tube or may have a non-circular cross-section. One end of the passive inhalation medium storage area 2413 may be limited by a passive bite piece 2415 or an inner wall feature (not shown). The other end of passive medium storage area 2413 can be limited by passive storage box connector 2411, exposed electrical contacts or other components (not shown). Passive drainage core (passive wick) 2416 is located in passive storage box housing 2412 and is communicated with the suction medium fluid. Passive drainage core 2416 can pass through one or more openings formed in internal air pipe 2414, passive storage box connector 2411, evaporation chamber or other internal components, so that suction medium is transferred to cylindrical heater 901 from passive suction medium storage area 2413, where suction medium can be evaporated and entrained in air flow, to be delivered to user via internal air pipe 2414 and passive bite piece 2415. Passive drainage core 2416 can be constructed by non-conductive porous material, and this non-conductive porous material transmits suction medium via capillary action. Such material can include but is not limited to: porous ceramic, non-conductive metal mesh, cotton, twisted or woven silica or other similar materials. In alternative embodiments, the passive drainage wick may be located within an interior component other than the interior air tube 2414 , such as an interior evaporation chamber that is fluidly connected to the interior air tube 2414 .

[0184] Passive inhalation medium storage box 2410 can also include memory IC 205, and it provides the function described previously in this document.Memory IC 205 can be electrically communicated with passive control device 2401 via the electric contacts arranged on or in passive storage box connector 2411.Passive storage box connector 2411 can also provide the electrical connection between passive control device 2401 and cylindrical heater 901.The shape of passive storage box connector 2401 can be designed to make it mechanically and electrically connected with passive control device connector 2408.Can provide mechanical alignment and interlocking feature portion on one or both of passive storage box connector 2401 and passive control device connector 2408, such as snap-on pawl and matching clearance, to ensure firm mechanical and electrical connection. Some versions of the passive vaporizer article 2400 eliminate the need for a passive cartridge connector 2411 by extending the passive inhalation media cartridge 2410 within the passive control device 2401 for mechanical alignment and interlocking, which typically uses a snap-fit ​​detent on the passive control device 2401 and a mating clearance on one or more outer surfaces of the passive inhalation media cartridge 2410, such as Figure 24b Such a system may generally be referred to as a "pod" system.

[0185] The passive control device 2401 may include a passive control device housing 2402, a battery 111, an inhalation sensor 119, a passive control circuit 2404, one or more indicator lights 104, and a lamp housing 2407. The passive control circuit 2404 may be substantially similar to the control circuit 120, but may lack one or more components, particularly the bidirectional motor drive circuit 1502. Because the passive vaporizer article 2400 delivers the inhaled medium to the cylindrical heater 901 via capillary action rather than an absolute delivery of a predetermined volume, certain features and dosing accuracy provided by the vaporizer article 10, the ingredient display enabling control device 2100, and / or the inline ingredient control device 3501 are not possible. However, the passive vaporizer article 2400 can approximate certain important features. Specifically, with respect to dosing, the passive control circuit 2404 can be configured to estimate the amount of the inhaled dose by measuring the duration of the inhalation and assuming that a certain amount of dose is delivered per unit time for a given set of vaporization parameters. The passive control circuit 2404 may also be configured to disable the cylindrical heater 901 when the desired dose level is reached via this dose delivery estimation method. The passive control circuit 2404 may also be configured to notify the user that the desired dose has been inhaled.

[0186] Suction sensor can be configured to detect the pressure change or the change of air flow rate caused by the suction of the user.Suction sensor can be replaced by a button or switch that can be manually activated by the user instead.Passive control device 2401 can be performed by control device 100, composition display enable control device 2100 and in-line composition control device 3501 to perform some functions, including but not limited to: be connected to computer network 1801, record dosage, send and receive dosing information, exchange data with computing device 1803, dosage compensation, remote dosing, control the temperature of cylindrical heater 901 and read and write data element to memory IC 205.For example, passive control device 2401 can be configured to read sequence number from memory IC 205 and check whether there is this sequence number in database 1600 before enabling the use of passive suction storage box 2410.An embodiment of passive control device 2401 can also include display screen (not shown), and this display screen is configured to show the composition of the suction medium contained in passive suction medium storage box 2410. The display screen may also be configured to display additional information regarding the inhalation medium, the passive inhalation medium cartridge 2410 , and / or the passive control device 2401 .

[0187] Some types of vaporizers operate by heating a solid medium, such as dried tobacco leaves. In such vaporizers, the solid medium is heated to a temperature well below the combustion temperature to produce an aerosol and its associated byproducts without combustion. The solid medium can be heated to or near the pyrolysis temperature of the material. The solid medium can be pretreated to promote aerosol formation. For example, the solid medium can be flattened, dried, granulated, mixed with a binder material, and / or mixed with an aerosol-forming substance, such as propylene glycol or glycerol. Fig.25A solid media vaporizer article 2500 is described that is capable of providing many of the functions and benefits provided by vaporizer article 10. The solid media vaporizer article 2500 includes a solid media control device 2510 and a solid media rod 2501. The solid media rod 2501 can be similar in form and composition to a conventional combustible cigarette; it can contain a solid media 2503 (such as ground tobacco leaves) and a filter 2504 wrapped in a wrapper 2502. The filter 2504 can be located between the solid media 2503 and the user's mouth to prevent inhalation of particulate matter. The wrapper 2502 can be made of cigarette paper to give it the feel of a combustible cigarette. The wrapper 2502 can alternatively be made of plastic, metal, wood, or other materials suitable for containing the solid media 2503. The wrapper 2502 can be located within an IC holder 2505. The wrapper 2502 may be adhered, woven, or attached to the IC holder 2505 in such a way that attempting to separate the two will result in destruction of the wrapper 2502 and render the solid dielectric stick 2501 unusable. This will discourage tampering with the IC holder 2505 and attempting to use it with other solid dielectric sticks 2501 or other devices.

[0188] The IC holder 2505 provides a physical and electrical attachment for the memory IC 205, which may contain substantially similar information as described previously in this document. When used in conjunction with the solid dielectric rod 2501, the memory IC 205 may additionally contain parameters specific to the solid dielectric rod 2501 embodiment. The memory IC 205 may be electrically connected to one or more solid dielectric electrical connectors 2507, which may be flexible metal contacts, spring-loaded pins, or conductive pad contacts. The IC holder 2505 may also have a solid dielectric alignment feature 2508 that facilitates mating with the solid dielectric control device 2510. The distal end of the solid dielectric rod 2501 may be inserted into the heating cavity 2521 of the solid dielectric control device 2510 so that the solid dielectric alignment feature 2508 is aligned with the solid dielectric guide feature 2519 located within the solid dielectric receiving ring 2518. When inserted, the solid dielectric electrical connector 2507 establishes an electrical connection with the one or more electrical connectors 108. When the solid medium rod 2501 is correctly inserted into the solid medium control device 2510, the solid medium 2503 can be substantially disposed within the heating chamber 2521 formed by the annular heater 2512. When the user inhales at the proximal end of the solid medium rod 2501, air enters the solid medium control device 2510 through the solid medium control device air inlet 2516 located in the wall of the solid medium control device housing 2511. The size of the solid medium control device air inlet 2516 can be used to determine the suction resistance of the device. The air then flows through the air sensor opening 2517 located in the air flow sensor 2514, which generates a signal that can be read by the solid medium control device circuit 2513, which in turn sends power to the annular heater 2512. The air sensor opening 2517 can also be used to determine the suction resistance of the device. When the annular heater 2512 is powered on, the solid medium 2503 is heated to the extent of forming an aerosol. The aerosol can be mixed and / or entrained in the airflow that passes through the filter 2504 and then enters the user's mouth. An auxiliary air inlet (not shown) may optionally be included at or downstream of the heating chamber 2521 to provide additional air to mix with the aerosol and produce a cooler aerosol for the user to inhale. In other embodiments, activation of the annular heater 2512 may be provided by other means such as an air pressure sensor 2613 or a button rather than by the airflow sensor 2514.

[0189] The solid medium control device 2510 may also include a battery 111 configured to provide power to the solid medium control device circuit 2513 and the ring heater 2512. The charging connector 103 may be used to provide energy to charge the battery 111. The solid medium control device circuit 2513 may include components for electrically controlling the charging of the battery 111.

[0190] Because the solid medium vaporizer article 2500 heats a large amount of solid medium 2503, rather than absolutely placing a predetermined volume of inhaled medium on a heater for vaporization, certain features and the dosing accuracy that may be provided by the vaporizer article 10, the component display enabling control device 2100, and the in-line component control device 3501 are impossible. However, the solid medium vaporizer article 2500 can approximate certain important features or provide alternatives to certain important features. One way to provide dosage control is to provide a dosing unit for each solid medium rod 2501. The solid medium rod 2501 can be sold at a predetermined dosing level, for example, in the case of a solid medium dosing rod containing tobacco, a rod with a nicotine level of 0.5 mg, 1.0 mg, 1.5 mg, and 2.0 mg can be provided. In both examples, the user can use one or more rods in combination to consume the desired dose.

[0191] Alternatively, the solid medium rod 2501 may include enough solid medium 2503 to provide multiple doses. When used in conjunction with such a solid medium rod 2501, the solid medium control device circuit 2513 may be configured to estimate the amount of the inhaled dose by measuring the duration of the inhalation and assuming that a certain amount of dose is delivered per unit time for a given set of heating parameters. The solid medium control device circuit 2513 may also be configured to disable the annular heater 2512 when the desired dose level is reached via this dose delivery estimation method. The solid medium control device circuit 2513 may also be configured to notify the user that the desired dose has been inhaled. The solid medium control device circuit 2513 may alternatively be configured to integrate the flow rate signal provided by the airflow sensor 2514 over the duration of the inhalation to determine the amount of the dose delivered to the user. As with the vaporizer product 10, the solid medium control device 2510 may be configured to allow the user to select a dose according to the desired ingredient, and may determine the inhalation duration required to deliver the desired amount of the requested ingredient. The solid media control device circuit 2513 can be configured to read the composition information from the memory IC 205 as one of the inputs to this determination. The solid media control device circuit 2513 can alternatively be configured to read the serial number or similar identifier from the memory IC 205 and then download it from the computing device 1803 or database 1600 as the dispensing amount information.

[0192] Another way to provide dosing control is to use a solid medium stick 2501 containing enough solid medium 2503 to provide multiple doses, and instead of measuring the duration of the inhalation and disabling the ring heater 2512 when the dose level is reached, only turn on the ring heater 2512 for a discreet duration for each inhalation. For example, the solid medium control device circuit 2513 can be configured to turn on the ring heater 2512 long enough to deliver 1 mg of CBD during each inhalation. If the user needs 3 mg of CBD, then he will take 3 inhalations.

[0193] The solid media control device 2510 is capable of performing many of the functions performed by the control device 100, the composition display enabled control device 2100, or the in-line composition control device 3501, including, but not limited to: communicating with the computer network 1801 and database 1600, recording and controlling dosage, sending and receiving dosing information, dosage compensation, remote dosing, exchanging data with the computing device 1803, controlling the temperature of the ring heater 2512, and writing data elements to or reading data elements from the memory IC 205. For example, the solid media control device circuit 2513 can read the serial number from the memory IC 205 and compare it to a list of known serial numbers to ensure that the solid media stick 2501 is not counterfeit. Alternatively, the solid media control device circuit 2513 can be configured to read information from the memory IC 205 and compare it to an expected format to verify that the solid media stick 2501 is authentic. The solid medium control device circuit 2513 may also be configured to implement a high-level security algorithm (e.g., SHA-256) in conjunction with the information stored in the memory IC 205 to prevent the use of unauthorized solid medium stick 2501. One embodiment of the solid medium control device 2510 may also have a display screen (not shown) configured to display the composition of the solid medium 2503 contained in the solid medium stick 2501. The display screen may also be configured to display additional information about the solid medium 2503, the solid medium stick 2501, and / or the solid medium control device 2510.

[0194] Some users may prefer to use a solid medium stick 2501 instead of a cartridge 200 because the solid medium 2503 tends to retain more chemicals responsible for taste, odor, physical and mental effects than the liquid isolates and distillates typically used in cartridges 200. However, many of these chemicals can be found deep within the material used to form the solid medium 2503 and may therefore not easily enter the aerosol stream. For clarity, this may be due to the physical distance between the ring heater 2512 and certain portions of the solid medium 2503 resulting in less heating of certain portions of the solid medium 2503. This may also be due to the fact that certain chemicals may be "locked" within the materials used to form the solid medium 2503 rather than being located on the surface of those materials, where the chemicals can be more easily volatilized by the ring heater 2512. One way to increase the presence of these chemicals in the aerosol is to pre-treat the material with a solvent and then dry the material before forming the solid medium stick 2501. Treatment with a solvent can "unlock" the chemicals from within the material, while the drying process tends to pull the chemicals toward the surface of the material as the solvent evaporates. In some embodiments, the present invention relates to the present invention to the terpene isolate of tobacco plant material. The terpene isolate of tobacco plant material can be sprayed on the plant material with terpene glycol. This makes the material surface enrichment chemical substances, thereby makes them more volatile. Many different solvents can be applicable to pre-treatment. Ethanol may be a particularly good solvent used together with tobacco plant material. Except or instead of pre-treatment with solvent so that some chemical substances are pulled to the surface of plant material, plant material can also be sprayed with some chemical substances or soaked in some chemical substances, so that these chemical substances are stayed on the surface of plant material, so as to volatilize easily. For example, terpene isolate (such as limonene) can be sprayed on the plant material, so that the fragrance and the taste of citrus fruits are provided. For another example, menthol can be sprayed on the tobacco plant material to provide mint taste.

[0195] Fig.26An optical solid medium evaporator article 2600 is described. The optical solid medium evaporator article 2600 is substantially similar to the solid medium evaporator article 2500, with the primary difference being that information relating to the solid medium 2503 is printed or otherwise encoded on the surface of the solid medium rod, where the optical solid medium evaporator article 2600 can read the information by optical means. In this embodiment, the components responsible for evaporation, charging, data exchange, and indication can be similar or even identical. The optical solid medium evaporator article 2600 can include an optical solid medium rod 2601 and an optical solid medium control device 2610. The optical solid medium rod 2601 can include a solid medium 2503 and a filter 2504 wrapped in a wrapper 2502. Instead of using a memory IC 205 contained by an IC holder 2505 to store information relating to the solid medium 2503, the optical solid medium rod 2601 includes an encoded wrapper portion 2602 that can be printed with optical information 2603. Optical information 2603 can represent any same type of information that can be stored in memory IC 205 as described earlier in this document. Optical information 2603 can be displayed in a machine-readable format such as a barcode or QR code. Encoded packaging part 2602 can be a part of packaging 2502, or can be a separate piece of material or band fixed or adhered to packaging 2502. Encoded packaging part 2602 can be formed, adhered, woven or attached to packaging with packaging 2502 in one piece, so that attempting to separate the two will cause the destruction of packaging 2502 and make optical solid medium rod 2601 unusable. In alternative embodiments, encoded packaging part 2602 can be replaced by wireless memory (such as RFID tag).

[0196] The optical solid medium rod 2601 can be inserted into the heating chamber 2521 and its distal end can be penetrated by the heater blade 2612. It should be noted that although the description of the optical solid medium evaporator article 2600 uses the heater blade 2612 instead of the ring heater 2512, the ring heater 2512 can be used instead of the heater blade 2612. Similarly, the solid medium evaporator article 2500 can use the heater blade 2612 instead of the ring heater 2512. When the optical solid medium rod 2601 is inserted into the optical solid medium control device 2610, the coded package portion 2602 can be aligned with the optical reader 2615. The optical solid medium rod 2601 can have an alignment feature (not shown) that cooperates with the alignment feature within the optical solid medium control device 2610 and facilitates the alignment of the optical information 2603 with the optical reader 2615. Alternatively, the optical information 2603 may be repeated at multiple locations around the coded packaging portion 2602 so that the optical information 2603 may be within the field of view of the optical reader 2615 regardless of orientation. In an alternative embodiment where the coded packaging portion is replaced with a wireless memory (such as an RFID tag), the optical reader 2615 may be replaced by an RFID reader.

[0197] When the user inhales at the proximal end of the optical solid medium rod 2601, air enters the optical solid medium control device 2610 through the optical solid medium control device air inlet 2616 located in the wall of the optical solid medium control device housing 2611. The airflow creates a pressure difference within the optical solid medium control device housing 2611 on one side of the air pressure sensor 2613, which generates a signal that can be read by the optical solid medium control device circuit 2617, which in turn sends power to the blade heater 2612. When the blade heater 2612 is powered, the solid medium 2503 is heated to a degree that an aerosol can be formed. The aerosol can be mixed and / or entrained in the airflow that flows through the internal air opening 2614, the solid medium 2503, the filter 2504, and then into the user's mouth. In alternative embodiments, activation of the blade heater 2612 can be provided by other means (such as an airflow sensor 2514 or a button) rather than the air pressure sensor 2613.

[0198] The optical solid medium control device 2610 may also include a battery 111 configured to provide power to the optical solid medium control device circuit 2617 and the blade heater 2612. The charging connector 103 may be used to provide energy to recharge the battery 111. The optical solid medium control device circuit 2617 may include components for electrically controlling the charging of the battery 111.

[0199] The optical solid medium vaporizer article 2600 can function in a manner substantially similar to the solid medium vaporizer article 2500. The main difference is that the optical solid medium control device 2610 cannot write data to the encoded packaging portion 2602, and the amount of data that can be encoded as optical information 2603 may be less than the amount of data that can be stored in the memory IC 205. These differences can cause limitations, including the inability to write usage information to the optical solid medium rod 2601, and certain types of advanced data security techniques may be impossible. The severity of the limitation of being unable to write usage data can be mitigated by storing such data in one or more memories located in the optical solid medium control device circuit 2617, the computing device 1803, and the database 1600. For example, each time a user inhales, the optical solid medium control device circuit 2617 can record certain usage data (such as puff duration), save the data to its local memory, and associate the data with a serial number or unique identifier encoded as optical information 2603. As the user performs subsequent inhalations, the optical solid medium control device circuit 2617 may increase the running total of inhalation durations associated with a particular serial number or unique identifier, and inhibit heating of the associated optical solid medium rod 2601 when a threshold associated with exhaustion of the optical solid medium rod 2601 is met. This process may also be performed at the computing device 1803 or computer network 1801 level. The severity of the data volume limitation of the optical information 2603 may likewise be mitigated by using information stored in the database 1600. For example, the optical information 2603 may simply include the serial number or unique identifier of a particular optical solid medium rod 2601. The database 1600 may include a record associated with the serial number or unique identifier, which is all information about the history, contents, and manufacturing of each optical solid medium rod 2601 produced. When an optical solid medium rod 2601 is inserted into the optical solid medium control device 2610, such a record may optionally be downloaded to the optical solid medium control device 2610 and / or computing device 1803. By accessing database 1600 and storing a local copy of the information in either the optical solid medium control device 2610 or the computing device 1803, the data required to perform the following functions can be obtained: recording and controlling dosage, sending and receiving dosing information, dosage compensation, remote dosing, and controlling the temperature of the blade heater 2612.

[0200] Fig.27aAn exemplary response curve 2701 to a single dose of a chemical or drug is described. Response curve 2701 can represent the concentration level of a chemical in the blood, i.e., the pharmacokinetics (PK) of the chemical. Response curve 2701 can alternatively be used to represent the effect of a chemical on a user, i.e., its pharmacodynamics (PD). For some chemicals or drugs, the curves representing the effect strength and the blood concentration can be substantially similar or even identical, while for other drugs, the curves can be different in shape, timing, and magnitude. The relationship between PK and PD can be quite complex for some chemicals and is affected by a variety of factors, however, pharmacologists can and have established PK / PD models for a variety of chemicals and drugs, i.e., mathematical expressions, which allow the time course of the effect strength to be described in response to the administration of a dose. For the purposes of this disclosure, response curve 2701 is generally referred to as a measure of effect strength, while noting that its use as a representation of blood concentration is not excluded from the present invention. The response curve begins at 2702 after the drug is administered or consumed. Then, as the drug is absorbed, the response increases until the maximum effect level 2703 is reached at the maximum effect time 2704. After reaching the maximum effect level 2703, the effect typically begins to decrease until the effect decreases to a minimum effect threshold level 2705, at which point the effect is considered no longer detectable, no longer influential, no longer inhibitory, no longer therapeutic, no longer effective, or no longer of interest. This occurs at a minimum effect threshold time 2706. The minimum effect threshold level 2705 may or may not be zero.

[0201] Figure 27b An exemplary multiple dose response curve 2712 is shown. The response to the first dose follows Fig.27a2701, however, at a second dose time 2713, a second dose of the chemical substance is administered or consumed. The second dose response curve is represented by dashed line 2711. Then, the multiple dose response curve 2712 begins to increase in response to the second dose. The multiple dose maximum effect level 2715 is reached at the multiple dose maximum time 2714. The minimum effect threshold level 2705 occurs at the multiple dose minimum effect threshold time 2716. When certain drugs saturate their target receptors, their effect level may have an upper limit. Therefore, for certain drugs, an upper limit can be applied to the multiple dose response curve 2712. In any vaporizer article embodiment including the ingredient display enabling control device 2100, the passive vaporizer article 2400, the solid media vaporizer article 2500, the optical solid media vaporizer article 2600, the in-line ingredient vaporizer article 3500, the medium delivery article 3600 and the nasal delivery article 4700, understanding the aforementioned response curve can be helpful to the user of the vaporizer article 10. Response curve models for drugs and chemicals (including but not limited to CBD and nicotine) can be created within the computer network 1801 and used to guide dosing, including in conjunction with the dosage recommendation process 2000.

[0202] While such models can help guide dosing, incorporating other inputs into the model can further improve the accuracy and applicability of the model on an individual basis. Fig.28It is shown that models can be created and refined within the computer network 1801. In box 2801, a general equation or model of effect response can be constructed within the computer network 1801 and stored in the database 1600. The model can be based on PK and / or PD studies previously conducted on a given chemical or drug. However, it is known that the response of a given drug or chemical may differ from the standard model based on the presence of other chemicals, which can promote, delay or otherwise change the response to the chemical for which the model was originally built. This allows the construction of a mathematical model. However, the solid medium can also contain many other chemicals. Through scientific research and / or data collected by the computer network 1801 and stored in the database 1600, the data analysis program 1805 can determine parameters that improve the accuracy of the response curve based on the chemical composition of the preparation that the user is consuming. In box 2802, such preparation-specific refinement parameters can be applied to the general equation 2801 to better predict the effect on the user. Such refinement parameters can be obtained through clinical testing, or can be determined by the data analysis program 1805 by analyzing the responses of users to various preparations at various doses. In addition, data analysis program 1805 can also know that a given user is using storage box 200, and storage box 200 contains a certain proportion of CBD, because its preparation composition information can be stored in memory IC 205 and / or database 1600. Given this information, data analysis program 1805 can provide recommended dose to the user with improved accuracy relative to universal model 2801. For example, the user can request data analysis program 1805 to suggest the dosage reaching a certain maximum effect level 2703. By determining the specific refinement parameter 2802 of the preparation and applying it to the universal model 2801, data analysis program 1805 can provide dosage recommendation 2807, which is more likely to produce the required maximum effect level 2703.

[0203] Characteristics of individual users, including but not limited to weight, age, gender, and current status, may also affect the accuracy of the generic model 2801. Using methods similar to those described in the discussion of formulation-specific refinement parameters 2802, user characteristic refinement parameters 2803 may also be determined via clinical methods and / or data analysis programs 1805 and then used to improve the accuracy of the generic model 2801. Dynamic influences including but not limited to recent alcohol consumption, recent consumption of certain foods, recent consumption of other drugs or chemicals, recent exercise, and recent sleep levels may also affect the accuracy of the generic model 2801. Using methods similar to those described in the discussion of formulation-specific refinement parameters 2802, dynamic influence refinement parameters 2804 may also be determined via clinical methods and / or data analysis programs 1805 and then used to improve the accuracy of the generic model 2801.

[0204] Due to various other reasons, including lack of data, the general model 2801 of a specific drug or chemical may not be as accurate as desired. In such cases, the data analysis program 1805 is very suitable for improving the general model 2801. The data analysis program 1805 can determine the group refinement parameters 2805 by analyzing multiple data records of multiple users stored in the database 1600, and the group refinement parameters can also be used to improve the accuracy of the general model 2801. For other reasons, the response of an individual to a given chemical or drug may deviate from the general model 2801. These reasons include, but are not limited to, individual differences in human chemistry, individual differences in metabolism, and individual tolerance to drugs or chemicals. In such cases, the data analysis program 1805 is very suitable for improving the general model 2801. The data analysis program 1805 can determine the individual refinement parameters 2806 by analyzing multiple data records from a single user stored in the database 1600, and the individual refinement parameters can also be used to improve the accuracy of the general model 2801. For example, data analysis program 1805 can analyze the response to the questions about the response of individual users to nicotine dosage that were communicated to individual users who frequently smoke nicotine via chat agent 1802 in the past. This analysis can show that the response of individual users to nicotine is lower than the response predicted by general model 2800. Then individual refinement parameters 2806 can be determined for the individual user, and the individual refinement parameters allow the model to better predict how the individual user will respond to a given dose of nicotine. It should be understood that refinement 2802 to 2806 can be applied independently, in any combination with each other, or not at all based on the configuration, user configuration settings and available data of the system. Although the general model 2801 and the refinement parameters are stored in the database 1600 to provide advantages, the model and / or refinement parameters can also be stored in any one of the control device 100, the component display enabling control device 2100, the in-line component control device 3501, the memory IC205 and / or the computing device 1803.

[0205] It should be understood that there may be situations where a model for a given drug or chemical does not exist or is not accurate enough to be used. In such situations, data analysis program 1805 can be configured to extrapolate effect-response predictions by analyzing the records of doses and responses stored in database 1600. This can be accomplished via one or more data mining techniques, including but not limited to: tracking patterns, classification, association, outlier detection, clustering, regression, and prediction.

[0206] Fig.29a shows how to combine Fig.27a , Figure 27b and Fig.28An example of using the composition display enabled control device 2100 using the model described in . In this example, the user enters in the menu 2902 the time at which they want the effect to wear off. This can be interpreted by the data analysis program 1805 as the time at which the user expects to reach the minimum effect threshold level 2705 after the peak effect has occurred. Using this input in conjunction with the previously described model, the data analysis program 1805 can determine the amount and timing of one or more doses that the user can take to achieve the desired time for the effect to wear off. In addition, the data analysis program can be configured to communicate this dosage and timing information to the user. In addition, the composition display enabled control device 2100 can be configured to deliver only the corresponding dose to the user, thereby ensuring that the user does not consume too high a dose and that the effect wears off at the desired time.

[0207] Fig.29b shows how to combine Fig.27a , Figure 27b and Fig.28 Another example of using the composition display enabled control device 2100 using the model described in . In this example, the user enters a desired effect intensity in menu 2903. The data analysis program 1805 can interpret this as a maximum effect level 2703 or a multi-dose maximum effect level 2715. Using this input in conjunction with the previously described model, the data analysis program can determine the amount and timing of one or more doses that the user can take to achieve the desired effect intensity. In addition, the data analysis program 1805 can be configured to communicate this dosage and timing information to the user. In addition, the composition display enabled control device 2100 can be configured to deliver only the corresponding dose to the user, thereby ensuring that the user achieves the desired effect intensity. In another example, the composition display enabled control device 2100 can be combined Fig.29a and Fig.29b to allow users to select the maximum effect strength and the time they want the effect to wear off.

[0208] Fig.29c shows how feedback can be provided to the database 1600 to communicate with Fig.27a , Figure 27b and Fig.28. The data analysis program 1805 can cause the component display to enable the control device 2100 to prompt the user to rate the effect intensity, as shown in the feedback prompt 2906. The user can provide such feedback in the rating menu 2904. This can be done at regular intervals, or at a time determined to be optimal by the data analysis program 1805. The feedback prompt can be triggered by the data analysis program 1805. For example, if the user consumes the inhaled medium for sleep, the data analysis program 1805 can prompt feedback 8 hours after the dose is consumed. For another example, if the user consumes the inhaled medium to relieve pain, the data analysis program 1805 can prompt feedback 30 minutes after the dose is consumed. Alternatively, the component display enables the control device 2100 to be configured to periodically solicit such feedback without being triggered by the data analysis program 1805. Providing such feedback can enable the data analysis program 1805 to improve its ability to accurately recommend doses. It should be noted that the rating menu 2904 can be used for more than just the rating of the effect intensity. Feedback prompt 2906 can seek feedback on any aspect of the dosage that can be rated, including but not limited to: satisfaction, sleepiness, happiness, anxiety, pain, seizure frequency, seizure intensity, alertness, motor function, coordination, mental acuity, creativity, and perceived effectiveness. In addition, data analysis program 1805 can be configured to enable the component display to control device 2100 to display challenging questions in order to test the user. Such questions can have properties that are difficult for non-awake people to answer correctly. Such questions can be constructed in the form of quizzes or memory challenges. The answers to such questions or the correctness of the answers can be provided to database 1600 so that data analysis program 1805 can be used to improve its prediction model.

[0209] Figures 30a to 30c Reflects Figures 29a to 29c They demonstrate that the computing device 1803 may alternatively or additionally provide Figures 29a to 29c As an alternative to the data analysis program 1805 triggering prompts and analyzing data, such activities can also be performed at the level of the ingredient display enabling control device 2100, the in-line ingredient control device 3501 and / or the computing device 1803. In yet another embodiment, such activities can also be distributed among multiple elements of the system.

[0210] Fig.31The time-out dosing process 3100 is described and can be used to deliver a dose to a user that will expire at a time desired by the user. The time-out dosing process 3100 begins in block 3101. In block 3102, the user causes the ingredient display control 2100 to enter an effect time-out mode. In this mode, the ingredient display control 2100 can only deliver a dose that will expire at a time set by the user in block 3103. In block 3104, the data analysis program 1805 uses the Fig.27a , Figure 27b and Fig.28 The model described in 1805 determines the dosage to be delivered to the user so that the minimum effect threshold level 2705 is reached at the desired time. Since the data analysis program 1805 knows the composition of the storage box 200 through the associated information in the database 1600 or by reading the memory IC 205, the correct amount of inhalation medium can be distributed to deliver the dosage. In frame 3105, authorization is sent to the component display control device 2100 from the computer network 1801 so that the consumption reaches the determined amount at most. In frame 3106, the authorization and the associated amount can be optionally communicated to the user. This communication can be displayed on any one of the computing device 1803 or the component display control device 2100. In frame 3107, the user starts the dosage by distributing and inhaling on the component display control device 2100. Then in frame 3108, the actual inhaled dosage is recorded in the database 1600. In frame 3109, the component display control device 2100 determines whether the user has inhaled the maximum dosage determined in frame 3104. If the user has inhaled the maximum dose, subsequent dosing / inhalation is disabled in box 3112 until it is determined in box 3113 that the time set by the user in box 3103 has expired. After the time expires, the ingredient display control 2100 is reset to the standard operating mode 3114, and the process ends in box 3115, at which time the user can take a subsequent dose again.

[0211] If it is determined in frame 3109 that the user has not inhaled the maximum dose determined in frame 3104, a loop involving frame 3110 is executed, in which the component display control device 2100 waits for a dispense or inhalation request / event, and periodically checks in frame 3111 to see whether the time set in frame 3103 has expired. If the time has not expired and no dispense request or inhalation event is detected, the loop continues to return to frame 3110. However, if the time expires, the process continues to frame 3114, which works as described above. If at frame 3111, the time has not expired, but a dispense request or inhalation event is detected, the process loops back to frame 3104, where the dose can be recalculated. This is necessary because if a long time has passed since the last dose / inhalation, the next dose may need to be adjusted to ensure that the effect will disappear at the time initially set by the user in frame 3103. As described above, the user may be prompted to provide feedback and / or ask challenging questions during the process, and the user may be prompted during the frame circled by frame 3116. It should be noted that the data analysis program 1805 can also trigger the ingredient display control device 2100 or the in-line ingredient control device 3501 to prompt the user for feedback and / or ask challenge questions after the process terminates at block 3115 in order to check that the confirmation effect has disappeared and / or collect other feedback that can improve its predictive ability. Fig.29a and Fig.30a Associated functional usage.

[0212] The overtime dosing process can be controlled entirely by the computer network 1801, entirely by the computing device 1803, entirely by the ingredient display control device 2100, by the inline ingredient control device 3501, or a combination thereof. It should also be noted that although the overtime dosing process 3100 is described in the context of the ingredient display control device 2100, the overtime dosing process 3100 can also be applied to other embodiments including the control device 100, the manual control device 300, the button control device 500, the passive control device 2401, the solid medium control device 2510 and the optical solid medium control device 2610, the inline ingredient vaporizer product 3500, the medium delivery product 3600, and the nasal delivery product 4700.

[0213] Fig.32a One example of how the ingredient display enabled control device 2100 may be used in a social context is shown. In this example, the user is prompted in the feedback prompt 2906 to rate how well the dose treated their symptoms in the rating menu 2904. Depending on how the user rates the dose, the ingredient display control device 2100 may prompt the user to share the dosing information and / or rating with other users. Figure 32bA social prompt 3203 is shown that allows the user to determine whether they would like to share a dose and with whom in a social menu 3204. The ingredient display enabled control device 2100 may be configured to allow the user to share dose information with other individuals or groups of individuals that may be preset by the user. After selecting the desired recipient, the user may send the dose by selecting a send button 3205. When this occurs, information about the dose, including but not limited to amount, composition, chemical identity, potency, brand name, product name, product type, and test results, may be sent to the recipient's ingredient display enabled control device 2100 via the computer network 1801. When the recipient receives the shared dose, the recipient may receive a notification via their computing device 1803 and / or ingredient display enabled control device 2100. Fig.32c It is shown that the recipient can be prompted in the social receiving prompt 3206 to select an action associated with receiving a dose in the social receiving menu 3207. The user can take a variety of actions based on the received dosing information. If the recipient has a storage box 200 containing a substantially similar inhalation medium composition, the recipient can command its component display enabling control device 2100 to distribute a shared dose so that they can experience it. If the recipient's storage box 200 does not contain a substantially similar composition, the recipient can be provided with an option to select one of the dose components and distribute it according to the amount of the component present in the shared dose.

[0214] The user can also take other actions in the social receiving menu 3207. For example, they can also view the dose to understand its associated information. They can also choose to save the dose for later use. The dosing information saved in this way can be stored in any one of the component display enabling control device 2100, computing device 1803, computer network 1801 or storage box 200. The option of finding the seller of the storage box 200 from the shared dose can be provided to the recipient. If the recipient does not have a storage box 200 of a composition substantially similar to the composition of the shared dose, this is particularly useful. Such an option can be a link that can provide information about the seller and can be displayed on any one of the component display enabling control device 2100 or computing device 1803. The recipient can also choose to comment on the dose. Such comments can take the form of a rating or comment inputted via the component display enabling control device 2100, or can be inputted via computing device 1803. The recipient can alternatively refuse to share the dose. If the recipient refuses to share the dose, a notification that the dose has been refused can be provided to the sender. Alternatively, the recipient may be provided with the option to decline the dose without notifying the sender.

[0215] In one embodiment, the third party including but not limited to the seller of storage box, the individual that does not have composition display enable control device 2100, the manufacturer of inhalation medium, doctor, health care organization, therapist and consultant can send such dosage information to the composition display enable control device 2100 and / or computing device 1803 of recipient.Such third party can use computer interface to specify dosage and send it to recipient via computer network 1801.The sending of this dosage information can be manually or automatically triggered via computer program.Also can trigger the sending of this dosage information to be consistent with the position of user.For example, if the user is configured to provide position information (such as GPS coordinates) to computer network 1801 by their computing device 1803, then data analysis program 1805 can be configured to send such dosage information when determining that the user is close to the store that sells storage box 200.

[0216] It should be noted that although the dose sharing functionality is described in the context of the ingredient display control device 2100, the dose sharing functionality may also be applied to other embodiments including the control device 100, the manual control device 300, the button control device 500, the passive control device 2401, the solid medium control device 2510 and the optical solid medium control device 2610, the in-line ingredient control device 3501, the sublingual control device 3601 and the nasal delivery product 4700. Figures 33a to 33c Reflects Figures 32a to 32c They demonstrate that the computing device 1803 may alternatively or additionally provide Figures 32a to 32c Same functions associated with them.

[0217] Fig.34a Another example of how the ingredient display enabling control device 2100 can be used to provide additional information to the user is shown. In this example, a welcome message is displayed in the welcome prompt 3401, and the brand of the product is displayed in the brand display 3402. This information can be displayed when the ingredient display enabling control device 2100 is turned on and / or the cartridge 200 is connected. Fig.34b Shown how to use composition to show and enable control device 2100 to provide another example of additional information to the user.In this example, in storage box prompt 3403, show the information about storage box, and in storage box information display 3404, show the brand of the suction medium in the storage box.When composition shows and enables control device 2100 to be opened, storage box 200 is connected and / or user selects the information to be displayed, can show this information.Except the brand of suction medium or replace the brand of suction medium, can also show the additional information about the suction medium in storage box 200 and storage box 200, for example chemical composition. Fig.34cAnother example of how the ingredient display enabling control device 2100 can be used to provide additional information to the user is shown. In this example, a test result message is displayed in the verification prompt 3405, and the results of the product test are displayed in the test information display 3406. This information can be displayed when the ingredient display enabling control device 2100 is turned on, the cartridge 200 is connected, and / or the user selects the information to be displayed.

[0218] Fig.35a and Fig.35b An inline ingredient evaporator article 3500 is shown according to one aspect of the present disclosure. The inline ingredient evaporator article 3500 includes an inline ingredient control device 3501 and an inline ingredient storage box 3510. The inline ingredient control device 3510 is substantially similar to the control device 100 and the ingredient display enabling control device 2100, with the main difference that the evaporator element 109 is not included in the inline ingredient control device 3510. The evaporator element 109 can be housed in the inline ingredient storage box 3510, which is substantially similar to the integrated storage box 1400 and the plug-in storage box 1450 of the storage box embodiment. The inline ingredient storage box 3510 can be connected and removable from the inline ingredient control device 3501. The inline ingredient control device 3501 can have a plunger door 3502, and the plunger driver 116 can extend through the plunger door. One or more guide features 3503 may be provided to assist in mating the inline ingredient cartridge 3510 with the inline ingredient control device 3501. A retention latch 3504 may also be provided to assist in retaining the inline ingredient cartridge 3510. The retention latch 3504 may include a magnet acting on a piece of ferrous material or a magnet located within the inline ingredient cartridge 3510. The retention latch 3504 may alternatively be a mechanical feature, such as a snap fit or an interference fit, wherein the feature is shaped to provide a slight mechanical interference.

[0219] Fig.36a , Fig.36b and Fig.36c A medium delivery article 3600 is shown according to one aspect of the present disclosure. The medium delivery article is substantially similar to the in-line ingredient vaporizer article 3500, except that the vaporizer element 109 is removed from the in-line ingredient reservoir 3510 to form an in-line sublingual reservoir 3610. In this embodiment, the medium inside the in-line sublingual reservoir 3610 can be taken orally and can be swallowed by the user or placed under the tongue to be absorbed by the sublingual tissue rather than being inhaled. The medium stored in the medium storage area 206 (in the sublingual tube 3612) can be delivered to the patient via the sublingual tube 3612. Fig.36b is shown in cross-section and in Fig.36c3612 is delivered directly into the user's mouth. The medium, which may be in liquid or powder form, leaves the sublingual tube 3612 via the tube opening 3613. In one embodiment, the sublingual control device 3601 may be the same as the in-line ingredient control device 3501. By reading the ability of the memory IC 205, the in-line ingredient control device 3501 can distinguish between the in-line ingredient storage box 3510 and the in-line sublingual storage box 3610 and control accordingly. This means that all functions provided by the in-line ingredient control device 3501, including but not limited to dose control, distribution, data recording and sharing, dose compensation and connectivity, can also be delivered in sublingual use applications; functions that are only particularly related to the generation of aerosols will not apply.

[0220] Fig.37a A withdrawal curve 3701 is described, which represents the amount of a chemical or drug that a user can take in order to gradually reduce the amount of the chemical or drug consumed without triggering undesirable side effects or symptoms. For example, a user who wishes to consume less nicotine may wish to slowly reduce consumption over time. The withdrawal curve can be prescribed by a third party (such as a doctor) and stored in the database 1600 so that the data analysis program 1805 can suggest a dosage to the user. Alternatively, the data analysis program 1805 can construct and suggest an individual's withdrawal curve 3701 based on dosing data collected from other users with similar withdrawal goals. The withdrawal curve 3701 can also be a mathematical expression derived from observations of test subjects participating in a withdrawal study. The withdrawal curve 3701 starts at an initial withdrawal dose time 3702 with an initial withdrawal dose level 3703. The user can define one or more of a withdrawal completion time 3704 and a withdrawal dose final level 3705. Then, based on such inputs, data analysis program 1805 may determine one or more of the shape of withdrawal curve 3701 , withdrawal completion time 3704 , and withdrawal dosage final level 3705 .

[0221] Figure 37b and Fig.37cAspects of a dose visualization application 2103 configured to notify and control withdrawal activities are shown. The application title 2104 can be configured to indicate withdrawal mode. The dose visualization application 2103 can display one or more withdrawal prompts 3711, and can also provide the user with an area to answer such prompts in one or more withdrawal settings menus 3712. The information entered by the user into the withdrawal settings menu 3712 can be used by the data analysis program 1805 to help calculate the withdrawal curve 3701 for the individual. In addition, as shown in the withdrawal settings menu 3712c, the user can provide feedback that can be used by the data analysis program 1805 to confirm that side effects are within an acceptable range, or if such side effects fall outside of an acceptable range, adjust the withdrawal curve. The data analysis program 1805 can further provide a recommended amount of medium 3714 for consumption. For example, for a user who initially consumes 4.0 mg of nicotine per day and is trying to stop using nicotine, the data analysis program 1805 can use the withdrawal curve 3701 to recommend a dose of 2.0 mg for a given day as a few days after the withdrawal process begins. In any of its embodiments, the user may be presented with the option to accept the 2.0 mg recommendation and command the vaporizer article 10 to only provide a maximum of 2.0 mg for the day by pressing the accept button 3715. The user may also monitor their progress in staying within the 2 mg dose via the withdrawal meter 3716. For example, if the user is advised to take 2.0 mg of nicotine for a given day, and the user already has 0.8 mg, the withdrawal meter may display a reading of 40%. The system may be configured to not allow further dosing for the day once the user reaches 100% of the recommended amount 3714. Fig.38a , Figure 38b and Fig.38c Demonstrates what the Dose Visualization Application 2103 offers and Figure 37b and Fig.37c How certain functionality is also shown may be provided in part by the ingredient display enabling control device 2100, the in-line ingredient vaporizer article 3500, and the media delivery article 3600. This provides the user with the option to input such information and track their progress in the most convenient manner.

[0222] Fig.39a An embodiment of a dose visualization application 2103 is shown that is configured to accept and display background information from a user, including but not limited to age, weight, gender, height, physical condition, mental condition, illness, usage history, external health data, external advisors, social networks, and reasons for the user's consumption of inhaled media. Fig.39b An embodiment of an ingredient display enabling control device 2100 is shown, and relatedly, an in-line ingredient vaporizer article 3500 and a media delivery article 3600 are shown, which are configured to receive and display information related to Fig.39aSome or all of the same information as shown in .

[0223] Sharing information via images and photography is a common practice in social networks, and users may wish to share their experiences with media inhaled or orally ingested via social networks. For example, a user may wish to share that a specific dosage of a specific preparation helps relieve back pain. Fig.40a and Fig.40b An embodiment of a dose visualization application 2103 is shown, which is configured to display certain information related to dosing on an image or digital photo 4001. Badge 4002 can be a graphical element placed on a digital photo 4001. Badge 4002 can include fields such as badge dose 4003, badge dose material 4004, badge effect 4005, and badge provider 4006. Badge dose 4003 can be a dose consumed by a user. Badge dose material 4004 can be a medium consumed by a user, for example, nicotine, CBD, or a combination thereof. Badge effect 4005 can be an effect that the user previously told the system that it is trying to achieve, or can be manually entered by the user to describe their current state. Badge provider 4006 can include a company or individual name, such as the name of a company that provides inhalation media, the name of a company that produces storage box 200, or the name of a company that produces vaporizer product 10, component display enabling control device 2100, in-line component vaporizer product 3500, medium delivery product 3600, or nasal delivery product 4700.

[0224] Fig.41 The dose enabled photo process 4100 is described. The dose enabled photo process 4100 begins at box 4101. In box 4102, a user requests the dose visualization application 2103 or any of the ingredient display enabled control device 2100, the in-line ingredient vaporizer article 3500, or the media delivery article 3600 to take a dose enabled photo. In box 4103, the feedback application 1804 launches a utility or application in which the user can take a digital photo 4001. In box 4104, the user can take the digital photo 4001. In box 4105, the dose visualization application 2103 places the badge 4002 at an initial location on the digital photo 4001. In box 4106, the user can be provided with the option of selecting the final location, style, color, content, and format of the badge 4002. In box 4107, a combined or merged image is created. In box 4108, the user can be presented with a social network (e.g., for Fig.39aIn block 4109, the user may alternatively or additionally have the ability to save the dose-enabled photo to their computing device 1803 for later use, including sharing the dose-enabled photo with a social network without going through the dose visualization application 2103. The dose visualization application 2103 may also be configured to apply the badge 4002 to photos that already exist on the user's computing device 1803, or to photos that are downloaded to the user's computing device 1803 from the network.

[0225] Figures 42a to 42d 1803 and the inline ingredient vaporizer article 3500. (Note: Although in Figures 42a to 42dIn-line ingredient vaporizer article 3500 is specified in the embodiment, but it should be understood that any vaporizer article 10 in any of its embodiments may be used, including ingredient display enabling control device 2100, passive vaporizer article 2400, solid media vaporizer article 2500 and optical solid media vaporizer article 2600, in-line ingredient vaporizer article 3500, medium delivery article 3600 and nasal delivery article 4700. ) Just as the functions and user experience of the mobile phone are defined by the applications running on the mobile phone, the system described in the present invention can provide various functions and experiences determined by the applications running on the computing device 1803 and computer network 1801 and the inhaled media or orally ingested media. The knowledge required to design different applications may be very specific to each individual application and difficult for any one party to possess. Therefore, a network architecture is provided to allow different parties with application-specific knowledge to design applications that provide specific functions. And it may be desirable to separate certain applications from other applications to allow for separate development and data management. For example, it may be desirable to use the inline component vaporizer product 3500 together with the inline component storage box 3510 filled with a nicotine solution as part of a nicotine withdrawal program. An application may be created to help determine when to provide a dose, the size of the dosing that should be used, and what type of behavioral queue should be provided to the user. Designing such an application may require a deep understanding of nicotine addiction and human behavior. A party with such knowledge may design an application that runs on a computing device 1803 and / or a computer network 1801. For many reasons, including but not limited to data confidentiality, the party may also manage data associated with its user base separately from users of other applications. In another example, it may be desirable to use the inline component vaporizer product 3500 together with the inline component storage box 3510 filled with a melatonin solution for insomniacs as part of a sleep assistant program. An application may be created to help determine when to provide a dose, the size of the dosing that should be used, and what type of user feedback should be collected. Designing such an application may require a deep understanding of sleep science and melatonin pharmacodynamics. A party with such knowledge can design an application that runs on the computing device 1803 and / or computer network 1801. In another example, it may be desirable to use the inline ingredient vaporizer article 3500 with the inline ingredient storage box 3510 filled with a CBD formulation as part of an anxiety reduction program. An application can be created to help determine when to provide a dose, the size of the dosage that should be used, and what type of user feedback should be collected. Designing such an application may require a deep understanding of psychology and CBD pharmacodynamics. A party with such knowledge can design an application that runs on the computing device 1803 and / or computer network 1801.The differences between these three applications highlight the need for an architecture that allows the various applications to be developed, run, and managed independently.

[0226] Fig.42a A non-gateway architecture 4200 is shown, where each application has a corresponding program running within the computer network 1801. Users can download a mobile application 4205 to their computing device 1803 to enable certain functions. The mobile application 4205 is configured to communicate with the network program 4201. The mobile application 4205 can also be configured to cause an application-specific interface 4206 to be displayed on the display screen 129. Such an application-specific interface 4206 can be preloaded into the in-line ingredient vaporizer product 3500, or it can be downloaded from the mobile application 4205 or the network program 4201. The mobile application 4205 can also customize the operating parameters of the in-line ingredient vaporizer product 3500. Data from the in-line ingredient vaporizer product 3500 and the mobile application 4205 is sent to the network program 4201, which in turn determines how to process the data and where to store the data. Certain data specific to the mobile application 4205 can be stored in the application database 4202. Other data or modified copies of data can also be stored in the database 1600. For example, the username and usage data may be stored in the application database 4202, while an anonymous copy of the usage data may be stored in the database 1600. Data and commands from the web program 4201 may be sent to the mobile application 4205 and on to the inline ingredient vaporizer article 3500.

[0227] Figure 42bA gateway architecture 4200 is shown in which applications communicate through a central network gateway program 4210. A user can select which application they wish to run using an application selector 4209, which can be part of a native application that the user pre-installed or downloaded in conjunction with purchasing the in-line ingredient vaporizer article 3500. When the user selects an application (e.g., an application associated with the network program 4201), the network gateway program 4210 communicates with the network program 4201 and causes the associated mobile application interface 4211 to be displayed. If the network program 4201 requires a specific interface, it can also cause an application specific interface 4206 to be displayed on the display screen 129. The application specific interface 4206 can be pre-loaded into the in-line ingredient vaporizer article 3500, or it can be downloaded from the network program 4201. Data from the in-line ingredient vaporizer article 3500 and the mobile device 1803 is routed through the network gateway program 4210, which determines where to send the data. Data and commands from the network program 4201 may be routed to the mobile device 1803 through the network gateway program 4210 and on to the inline ingredient vaporizer article 3500. The network program 4201 may also issue requests to the network gateway program 4210 to cause certain actions to occur on the inline ingredient vaporizer article 3500. For example, the network program 4201 may send a request to the network gateway program 4210 to send a dosage recommendation to the inline ingredient vaporizer article 3500. The network gateway program 4210 may receive the request and send the command to the computing device 1803 in a format that the local application can understand. The network program 4201 may read data from the application database 4202 and store the data in the application database. The network program 4201 may also cause data or a modified copy of the data to be stored in the database 1600. It may also read data from the database 1600. In addition, the network gateway program 4210 may be configured to route certain data directly to the database 1600 and to route certain data from the database. The foregoing description of the gateway architecture 4200 describes an implementation in which a native application is used to display a specific mobile application interface 4211, however, it should be noted that there are implementations in which the application selector 4209 causes a separate application to be installed on the computing device 1803.

[0228] Figure 42bAlso described is how the gateway architecture 4200 works when the computing device 1803 is not present. In embodiments where the inline ingredient vaporizer article 3500 is configured with the necessary circuitry to connect directly to the computer network 1801, applications can still be selected and executed on the computer network 1801. In such embodiments, the inline ingredient vaporizer article 3500 may be equipped with Zigbee, Wi-Fi, or digital cellular circuitry configured to connect to the computer network 1801. In such embodiments, a user may select an application (such as a network program 4203) using a device application selector 4212, which may be preloaded onto the inline ingredient vaporizer article 3500. The network gateway program 4210 may establish a connection to the correct program. If the network program 4203 requires a unique interface, the network program 4203 may cause a device application interface 4208 to be displayed on the inline ingredient vaporizer article 3500. The device application interface 4208 may be preloaded onto the inline ingredient vaporizer article 3500, or it may be downloaded from the network program 4203. Once the device application interface 4208 is displayed, the user may access the functionality of the network program 4203 if operation of the network program 4203 is desired, and data exchange and command communications between the in-line ingredient vaporizer article 3500 and the network program 4203 may be facilitated by the network gateway program 4210 as previously described. Fig.42c shows a similar Figure 42b The only difference is that the application is selected by the device application selector 4212 instead of the application selector 4209.

[0229] Fig.42d A distributed architecture 4240 is shown in which different applications run on different computer networks 1801a-1801c. One benefit of this architecture is that each party can have more direct control over data and data privacy within their respective computer networks. In this architecture, there is still the option of using a network gateway program 4210 to help connect to the correct network program and send commands to the in-line ingredient vaporizer article 3500, however, the preferred communication path for non-anonymous user-related data is to connect directly to the appropriate network program. Although not shown, embodiments of the application selector, device application selector, and direct communication between the in-line ingredient vaporizer article 3500 and the network program can be implemented within the distributed architecture 4240. (Note: Although in Figures 42a to 42d3500, but it should be understood that any vaporizer article 10 in any embodiment thereof, including the ingredient display enabling control device 2100, the passive vaporizer article 2400, the solid media vaporizer article 2500 and the optical solid media vaporizer article 2600, the in-line ingredient vaporizer article 3500, the media delivery article 3600, the nasal delivery article 4700 and their corresponding components, can include this functionality. )

[0230] In some cases, rather than having the user select an application, it may be more convenient or desirable to select an application based on the characteristics of the cartridge and / or the inhaled medium or orally ingested medium. Fig.43a and Figure 43b Describes how the action of connecting an inline ingredient storage box 3510 to an inline ingredient control device 3501 can cause a particular application to be executed. (Note: Although Fig.43a and Figure 43b 3500, but it should be understood that any vaporizer article 10 in any embodiment thereof, including the ingredient display enabling control device 2100, the passive vaporizer article 2400, the solid media vaporizer article 2500 and the optical solid media vaporizer article 2600, the in-line ingredient vaporizer article 3500, the media delivery article 3600, the nasal delivery article 4700 and their corresponding components, can include this functionality. ) Figure 43bThe application selection process 4300 is described. When the user connects the cartridge 3510 to the inline ingredient control device 3501, the application selection process 4300 starts from box 4301. In box 4302, the inline ingredient control device 3501 reads the memory IC 205. Then, in box 4303, the inline ingredient control device 3501 compares the data elements associated with the application with the list of data elements stored in the memory 1503. If a match is found, then in box 4304, the inline ingredient control device 3501 will cause the correct corresponding application to be launched. The selection and launch of the corresponding application can be triggered by the inline ingredient control device 3501 sending a notification message to any one of the computing device 1803 or the computing network 1801. If the complete list of application data elements is not stored in the memory 1503, an alternative method of launching the corresponding application can be used. In this case, in box 4305, the inline ingredient control device 3501 sends a notification to the computer network 1801. The notification may contain the application data element read from memory IC 205. The application data element may be a unique element, or the system may use another data element, such as a serial number, for cross-reference purposes in database 1600. In block 4306, the network application may select the appropriate application based on comparing the application data element read from memory IC 205 to a list of application data elements stored in database 1600. When a match is found, in block 4307, the network application may trigger the corresponding application.

[0231] Fig.44a An application interface 4401 is depicted, shown in the context of an inline ingredient control device 3501, representing an exemplary application according to one aspect of the present invention. A user can select their pain level using a visual analog scale, and then using all available data about the user, other users in the network, and the pharmacodynamics of the inhaled medium, the application can recommend an appropriate dosage corresponding to that pain level. It should be noted that Fig.44a The visual analog scale shown is a representation of the Wong-Baker Facial Expression Pain Rating Scale. Alternative visual analog scales may be implemented for applications configured to provide dosing recommendations for other conditions, including but not limited to anxiety, depression, concentration, tremor, intestinal discomfort, smoking urges, and appetite management. Figure 44b It is demonstrated that these applications can be run on an alternative embodiment such as a passive control device 2401 if configured with a display screen. Fig.44c An application is shown that enables the consumer to dose according to the time they want the effect to wear off. The user selects a time and the application determines the appropriate dose that will wear off at the selected time. Fig.44d An application to display the composition of inhalation media is described. Figure 44e An application that solicits feedback from a user about the intensity of the effect or other characteristics of the dosage at a specific moment is shown. An application that can employ artificial intelligence technology uses available information to determine the best time to solicit such feedback. It can also determine the most appropriate question to ask. For example, in addition to the digital scale question, the application can also ask questions from the Amsterdam Resting State Questionnaire, the Brunel Mood Scale Questionnaire, the Test of Nicotine Dependence (FTND), the Minnesota Nicotine Withdrawal Scale (MNWS), the Schiffman Craving Scale (SCS), the Wisconsin Smoking Cessation Scale (WSWS), the Cessation Scale (CWS), the Mood and Physical Symptom Scale (MPSS), the Questionnaire on Smoking Desire (QSU) or the Smoking Addict Disease Scale (Schneider) of a single rating. Such a feedback interface can also be used to "log in" a new user; background information is collected by asking a series of questions, including but not limited to: age, weight, sex, physical condition including disease, mental condition and disease of the user, previous consumption of other inhaled media, medicine and drug use, and the reason why the user consumes the inhaled media. Feedback can be stored in a database (such as database 1600). Figure 44f An application is described that recommends a dose of a currently installed inhalation medium that provides an equivalent effect to another substance. For example, a user may want an effect equivalent to a specific amount of alcohol. In this example, the application can use available data to recommend a dose of inhalation medium that provides an approximately equivalent effect. This application can also be used to provide an equivalent effect between inhalation media of different compositions.

[0232] Figure 44g An application is shown that uses dosing information, available data, and optionally a pharmacodynamic model to predict when the effect of a dose will be felt by the user. Figure 44h An application that helps a user determine and / or recommends the timing, dosage, and formulation of an inhalation medium to be taken to aid insomnia is shown. The application can also determine when to ask for feedback from the user regarding the user's sleep quality. Figure 44i Shown is an application program for displaying the brand information about the inhalation medium. When in-line composition storage box 3510 was connected to in-line composition control device 3501, application program can read the serial number of in-line composition storage box 3510, and compare it with the serial number list associated with a given inhalation medium type, name or brand. Then can show one or more images associated with this inhalation medium on display screen 129. Such image can convey information, includes but not limited to: brand trademark, product image, the local flavor of inhalation medium and the purchase position of inhalation medium. Figure 44jAn image of a flavor display application is shown. In certain embodiments, the flavor of the currently attached inhalation medium may be unknown or have a predetermined image that conveys flavor characteristics. The flavor display application can analyze the ingredients of the inhalation medium and create a flavor graphic image corresponding to the levels of certain ingredients in the inhalation medium, which ingredients can be stored on any one of the memory IC 205, computing device 1803, or database 1600. Figure 44k An application for displaying information about the currently installed suction medium is shown. Figure 44i Same as described in . Figure 44l Shown is an application program for displaying the amount of the remaining suction medium in a given storage box. The initial position of plunger 204 can represent the full state of the storage box. By downloading or being programmed into the in-line composition control device 3501 or by being stored in the memory IC205 as a data element, the system can be made to know the maximum travel position of plunger 204, which can represent the fully empty state of the storage box. By knowing the current position of these two information and plunger 204, the application program can determine the amount of the remaining suction medium and display this information to the user. When the amount of the suction medium drops below the threshold, the application program can provide the user with the notification that the in-line composition storage box 3510 is running out. The application program can also be configured to estimate when the in-line composition storage box 3510 will become empty for the user according to the current rate of consumption. Corresponding notification can also be sent to other parties, including but not limited to: retailers, suction medium manufacturers, distributors, social networks and health care providers. Notification can also be configured to send to a purchasing system to order other in-line composition storage boxes 3510.

[0233] Figure 44m An application for promoting the purchase of an inhalation medium is shown. An example use of the application is to promote the purchase of an inhalation medium, such as in conjunction with receiving a notification that the amount of inhalation medium in a cartridge is below a threshold amount. Figure 44m The application can also facilitate the purchase of an inhalation medium selected from a list displayed on the display screen 129 or suggested via a message or notification. The application can be connected to an order fulfillment and payment processing service to purchase the product. The application that facilitates purchases can also be combined with an application that provides coupons to incentivize purchases, such as Figure 44n The application can determine when to send coupons and the value of the coupons by analyzing available information, such as previous purchase behavior and consumption data. The application can also send coupons triggered by the actions of third parties. For example, different users in the user's network can share recommendations for a particular inhaled media, which may cause the application to send coupons. In addition, third parties, such as sellers of inhaled media, can send coupons to users. Fig.44oAn application is shown that allows a user to switch between profiles, thereby allowing multiple users to use the same inline ingredient control device 3501 while still associating the data with the correct user and applying the appropriate user-specific settings. This application can also enable a guest mode, where the collected data is not associated with any specific user, nor are any specific user-specific settings applied. Figure 44p An application is shown that allows a user to rate a given inhalation medium. The application may provide a user with the opportunity to rate the inhalation medium after consumption. The ratings for a given inhalation medium may be stored in database 1600 or in a separate database. The cumulative rating and the number or multiple ratings may be displayed for other users to view. Users who provide ratings may earn rewards in exchange for providing such ratings. Figure 44q As shown, users can also share their ratings with other users or groups in the connected network. The application can also be configured to share dosing information. For example, the application can share the amount and chemical composition of the dose consumed by the user. The application can also share other information, including but not limited to: brand name, product name, time of consumption, location of consumption, product image and effect characteristics. The application can enable users to control which individuals or groups receive the shared information.

[0234] Figure 44r Shown is another type of information sharing, i.e. geographical location. In this embodiment, this application can enable the user to record and / or share the position of the inhalation medium that they consume each dosage. This application can be configured to record the position of each dosage when activated. If equipped with GPS or similar positioning technology, then the position information that can be provided from computing device 1803 or in-line composition control device 3501 determines the position. This position can be stored in the database 1600, and this application can also be configured to allow the user to make notes to this position. Dosage information and / or the information relevant to inhalation medium can also be recorded in the database 1600 and be associated with the position. Figure 44s Shows Fig.44a Another embodiment of a visual analog scale is shown. Based on the user's indicated urge to smoke, available data about the user, data from other users in the network, and the pharmacodynamics of the inhaled medium, the application can recommend an appropriate dose of nicotine or a tobacco replacement inhaled medium to reduce the urge to smoke. Figure 44tAn embodiment of an application configured to notify and help users achieve their quitting goals is shown. In this embodiment, a daily budget for nicotine consumption is provided to the user, and information about their current consumption is also provided to the user. The application can also be configured to automatically determine an appropriate daily budget based on a variety of factors, including but not limited to: the user's previous usage pattern, the usage pattern of other users in the network, a decreasing dosing model, a quitting model, a calendar event, the start date of the quitting plan, and the target end date of the quitting plan. The application can be configured to temporarily prohibit further consumption of inhaled media if the daily budget is exceeded. In addition, the application can be configured to display and / or determine the budget at different time scales, including but not limited to: hourly, daily, weekly, and monthly. Behavior modification techniques can be used to improve the effectiveness of the quitting plan. Figure 44u An embodiment of an application configured to provide messages to a user is shown, which is designed to improve the results of a quit plan via a behavioral queue. Well-timed encouraging messages can help users maintain compliance with the quit plan. Similarly, well-timed messages describing the negative consequences of violating the quit plan may cause the desired behavioral results. The application can be configured to monitor the user's previous usage patterns, usage patterns of other users in the network, decremental dosing models, quit models, calendar events, start dates of quit plans, and target end dates of quit plans to determine the best time to deliver such messages. The application can also be configured to determine the content of the message based on the above inputs. For example, if a user has a pattern of consuming extra inhaled media on Friday nights, the application can send a message to the user on the following Friday afternoon encouraging reduced consumption to preempt possible overconsumption next time. The application can also be configured to receive messages from other users on the network describing their progress in achieving their quit goals. The application can also be configured to deliver such a message when the inline ingredient control device 3501 detects that it has been picked up or opened after a period of inactivity. This may be determined by the user touching one of the input controls of the inline composition control 3501 , or by a signal from the optional accelerometer 1514 .

[0235] 44V depicts an application configured to display the operating status of the inline ingredient control device 3501. A number of operating status elements may be displayed, including, but not limited to: battery state of charge, battery charging progress, time to charge complete, time to battery depleted, wireless communication connection status, operating mode, operating errors, and connection status of the inline ingredient reservoir 3510. Figure 44wAn application is shown that is configured to display a history of inhaled media used in conjunction with the inline composition control device 3501. Descriptions of inhaled media known through the processes described earlier may be stored in one or more of the inline composition control device 3501, the computing device 1803, and the database 1600. The consumption history of the associated inhaled media may be displayed to the user in a variety of orders including, but not limited to: chronological order, frequency, cost, total consumption, popularity, and rating. Figure 44x An application configured to call up a user's most frequently consumed or favorite inhaled media is shown. The application can be configured to allow a user to construct, organize, and call up inhaled media lists. The application can also be configured to allow a consumer to create multiple lists, for example, a user can create one inhaled media list for pain relief and a second inhaled media list for insomnia. Figure 44y An application is described, which is configured to broadcast a dosing event stream to other users or groups within a network, without the user having to actively trigger each dosing event to be sent to a specific individual or group. When a user consumes a dose of inhaled media, information about the dose, including but not limited to user name, amount, brand name, product name, product type, consumption time, consumption location, product image and effect characteristics, can be sent to the recipient of the dosing stream. The application can be configured to allow the user to create a group and select the recipient of the dosing stream. The application can be configured to store the dose in a database 1600. The application can also be configured to automatically delete or anonymize the dose stream events stored on the database 1600 after a configurable or predetermined time period. Figure 44z An application configured to receive and display such dosing flow events is shown. The application can cause such notifications to be displayed on any of the display screen 129, computing device 1803, and smart watch 1806. The application can also be configured to display a summary of recent dose activity for each group on the network. The application can also be configured to allow the user to select individual dose events to display more information about such doses. The application can also be configured to allow the user to delete notifications. The application can be configured to automatically delete such notifications after a configurable or predetermined period of time.

[0236] Figure 44aa An application configured to restrict the use of the inline ingredient control device 3501 via the use of a password is shown. The application can be configured to allow a user to establish a custom password. The password can contain one or more letters, numbers, symbols, or patterns. The password can be stored in one or more of the inline ingredient control device 3501, the computing device 1803, and the database 1600. The password can also be specific to the cartridge and can be stored additionally in the memory 205. Figure 44bbAn application configured to implement the remote dosing process 2300 is shown. Figure 44cc An application configured to implement all or part of the dose-enabled imaging process 4100 is shown. The application can be configured to trigger blocks 4102 and 4105. It should be noted that Figure 44a to Figure 44cc The applications described in the can be configured to reside entirely or partially locally on the inline ingredient control device 3501 and / or computing device 1803, can be downloaded entirely or partially to the inline ingredient control device 3501 and / or computing device 1803, or can reside entirely or partially on the computer network 1801. In addition, the applications can be combined into a variety of combinations to provide unique combinations of functionality. It should be further understood that although the inline ingredient control device 3501 is used in the context of the description of the application, the application functionality can be implemented in conjunction with other embodiments of the control device 100, such as the ingredient display enabled control device 2100, the solid medium control device 2510, the optical solid medium control device 2610, the sublingual control device 3601, or a dedicated nasal delivery product 4700 (not shown).

[0237] Fig.45a An embodiment of a system is described that is configured to associate users on a computer network 1801, for example to share dosing information as previously described herein. A first in-line ingredient control device 3501 belonging to a first user can have an established connection with a computing device 1803 that also belongs to the first user. The computing device 1803 can be configured with an interface / application for associating with other users. The user can trigger the interface to cause the computing device to look for a signal from a second in-line ingredient control device 3501. The second user can configure the second in-line ingredient control device 3501 to send a signal that broadcasts an identifier unique to the second in-line ingredient control device 3501. The computing device 1803 can receive the signal and record the identifier. The interface / application can send the identifier to the computer network 1801, where the identifier can be matched with the account of the second user and can be configured to be associated with the first user. Fig.45b An alternative embodiment for establishing a connection between users on a computer network 1801 is shown. When a first second inline ingredient control device 3501 and a second second inline ingredient control device 3501 are tapped together, the respective accelerometers 1514 may generate a signal that is interpreted by the respective MCUs 1501 as a trigger to broadcast their respective identifiers and record the identifiers being broadcast. These identifiers may then be used to make associations as described above. Alternatively, the network 1801 may be configured to automatically associate users whose devices simultaneously experience a tap event within a particular geographic radius identified by the computing devices 1803 of the first user and the second user.

[0238] Fig.46a An embodiment is shown for providing the user with operating instructions 4601. The operating instructions 4601 may be displayed on the display screen 129. The operating instructions 4601 may include text characters, one or more static images, video animations, or a combination thereof. Fig.46bShown is an inhalation standardization process 4600 that can be configured to control the transmission of specific operation instructions 4601. The specific operation instructions in this example are related to the standardization of the inhalation medium holding time. In order for the dosage to reach the desired effect, it may be necessary to keep it in the lungs for a period of time. In addition, standardizing the inhalation medium holding time of the entire group can reduce the difference in results and effects. The process starts at frame 4602. When inhalation is detected in frame 4603, instructions are displayed in frame 4604. In this example, the instruction is displayed for 3 seconds, and then an exhalation instruction is provided in frame 4606. Optionally, if the instruction includes a series of images or animations, such as a countdown timer, a series of images or animations can be displayed in frame 4605 before proceeding to frame 4606. In order to provide additional notification of exhalation to the user, frame 4607 can be optionally implemented to open the vibration transducer 124 within a period of time to signal the user that the exhalation has been performed. Alternatively, the system can be configured to activate the vibration transducer 124 during the countdown, and then the vibration transducer is deactivated when the countdown is completed. The process terminates in frame 4608. It should be noted that other operating instructions can be displayed on the display screen 129, including but not limited to: a countdown timer indicating how to wait for the plunger driver 116 to fully retract before removing the inline ingredient storage box 3510, how to connect the inline ingredient storage box 3510 to the inline ingredient control device 3501, when to take a dose during meditation, and how to share a dose with other users in the network. Another embodiment of the operating instruction can be considered as a "demonstration mode", in which a series of images, texts, videos and / or instructions are displayed on the display screen 129, regardless of the user's input. The display of images, texts and / or instructions can be configured to repeat until the user turns off the demonstration mode. The inline ingredient control device 3501 can be configured not to perform other functions in the demonstration mode. For a retail environment, the demonstration mode may be an ideal function, in which the inline ingredient control device 3501 can provide information to potential buyers without relying on retail personnel to provide such information. For example, the inline ingredient control device 3501 can be configured to be in a demonstration mode and placed in a display case in a store. It should be further understood that although the inline ingredient control device 3501 is used in the context of the description of the operating instructions and demonstration mode, such functionality can be implemented in conjunction with other embodiments of the control device 100, such as the ingredient display enabled control device 2100, the solid media control device 2510, the optical solid media control device 2610, the sublingual control device 3601, or a dedicated nasal delivery product 4700 (not shown).

[0239] Fig.47a and Figure 47bA nasal storage box 4710 is shown according to one aspect of the present disclosure. The nasal storage box 4710 is designed to work with embodiments of the control device 100, such as an in-line component control device 3501, a sublingual control device 3601, or a dedicated nasal delivery article 4700 (not shown), which is substantially similar to the in-line component storage box 3510, except that the evaporator element 109 is replaced by a sprayer 4701. The sprayer 4701 may include an actuator / motor, a chamber, and a nozzle configured to pressurize the medium so that the medium is forcibly discharged from the sprayer 4701. In this embodiment, the medium inside the nasal storage box 4710 can be delivered to the nasal passage of the user. The medium stored in the medium storage area 206 can be distributed / fed into the sprayer 4701, and then directly delivered to the nasal passage of the user via the nasal tube 4702 after leaving the sprayer 4701. By reading the ability of the memory IC 205, the in-line ingredient control device 3501 can distinguish between the in-line ingredient cartridge 3510, the in-line sublingual cartridge 3610, and the nasal cartridge 4710. Using this distinction, each cartridge can then be controlled accordingly. This means that all functions provided by the in-line ingredient control device 3501, including but not limited to dose control, dispensing, data logging and sharing, dose compensation, and connectivity can also be delivered in nasal applications; functions specifically related to generating aerosols will not apply.

[0240] The consumption of cigarettes is usually divided into several stages, which depend to a great extent on the consumption time of cigarettes. In addition, the number and timing of the stages are usually similar every day, and are usually associated with regular behaviors (such as breakfast, work breaks, lunch breaks, after dinner, etc.) in time. On average, a standard length of 80mm with a filter cigarette can provide about 10 inhalations. Before extinguishing the cigarette, the user needs to inhale about 7 times on average. And most users inhale 1 cigarette per stage. Within a single user, the number of inhalations per cigarette and the duration of each inhalation usually do not vary significantly. Fig.48a Represents the standard consumption phase for a typical smoker, during which the user takes multiple inhalations until their typical maximum number of inhalations "Puff #n" is reached, with intervals between each inhalation. The duration of each inhalation is relatively the same as the other inhalations, so the total amount of active ingredient delivered, represented by the standard dose line 4801, is relatively similar in all inhalations. (Note that as the cigarette is consumed, the chemical composition will change due to distillation over time and from successive inhalations, but this is considered small and is not addressed in this discussion.) The same is true for traditional e-cigarettes where the duration of each inhalation does not vary significantly, however, because the duration of e-cigarettes is much longer than that of combustible cigarettes, the phases are less well defined and less constant.

[0241] To provide improved withdrawal functionality, the Fig.48a The standard consumption mode shown is an embodiment of the present invention, and it is composed of Fig.48b 4801. The electronic vaporizer is shown as a gradually decreasing consumption stage. Although electronic vaporizers generally do not limit the number of inhalations, the gradually decreasing consumption stage will limit the number of inhalations per stage. This number can be similar to the number of inhalations provided by combustible cigarettes, can be set to a number determined by user testing, or can be dynamically determined by an application that monitors the user's consumption pattern, the consumption pattern of other users of the network, and / or the feedback of network users, so as to recommend the best number of puffs per stage for a single user. The defined downtime / inactivity time period between stages can also be determined by the above method. In addition, during the entire stage, the amount of active ingredient delivered per inhalation can be programmatically reduced. The first inhalation or the first few inhalations of the combustible cigarette smoking stage will generate the greatest effect and the greatest degree of craving satisfaction. Subsequent inhalations in a stage will reduce the effect and satisfaction. Some users continue to smoke combustible cigarettes even after reaching a fully satisfied level out of habit or the feeling that a part of the cigarette should not be wasted. The gradually decreasing consumption stage can be configured to deliver the maximum amount of active ingredient during the first inhalation stage. Such an amount can reach the standard dose line 4801. Subsequent inhalations can be configured to continuously reduce the amount of active ingredient delivered until the minimum acceptable dose 4802 is reached. Minimum acceptable dose 4802 can be configured to deliver the minimum amount of active ingredients required to provide the necessary effect, taste and / or satisfaction to the user. For example, the amount of active ingredients delivered by each inhalation can be reduced linearly between the initial inhalation and the inhalation that reaches the minimum acceptable dose. Alternatively, the amount can be reduced in a nonlinear manner, such as decayed by a second-order or multi-order equation. The rate of change can be a fixed formula determined by user testing, or can be dynamically determined by an application program that monitors the consumption pattern of the user, the consumption pattern of other users of the network and / or the feedback of the network user, so as to suggest the best decay rate for a single user. The gradually decreasing consumption stage can be implemented in conjunction with any embodiment of the control device 100, and these embodiments include ingredient display enabling control device 2100, solid medium control device 2510, optical solid medium control device 2610, in-line ingredient control device 3501, sublingual control device 3601 and dedicated nasal delivery product 4700.

[0242] Fig.48cIndicates how the drive signal to the evaporator element 109 can be controlled to reduce the amount of active ingredient delivered during inhalation. During the inhalation process, the modulation signal 4807 delivers a constant amount of energy to the evaporator element 109. The modulation signal 4807 is also provided at the maximum PWM level 4805. The modulation signal 4807 can usually be used for the first inhalation of the stage. As the amount of active ingredient to be delivered decreases, the modulation signals 4808 to 4810 can be used to reduce the energy transferred to the evaporator element 109. The modulation signal 4808 starts with the maximum PWM level 4805 to produce an initial user sensation of inhalation comparable to the first inhalation, but then decreases during a portion of the inhalation process to reduce the amount of energy and the amount of inhaled medium that is thus evaporated. Then, depending on the duration of the inhalation, the modulation signal 4808 can be increased to maintain the user's perception. The modulation signal 4809 represents an alternative method to reduce the amount of active ingredient delivered. During the duration of the inhalation, the signal remains constant at a lower level than the modulation signal 4807. The modulation signal 4809 can be reduced to as low as the minimum constant PWM level 4809, which is the minimum signal required to produce a satisfactory inhalation. The modulation signal 4810 represents another method of reducing the amount of active ingredient delivered. The modulation signal 4810 starts at the maximum PWM level 4805 for a period of time, but can be reduced during the rest of the inhalation period. The modulation signal 4810 can be reduced to a level below the minimum constant PWM level 4809. It should be understood that the basic goal is to modulate the power delivered to the evaporator element 109 in order to control how much inhaled medium is evaporated. As long as the resistance of the evaporator element 109 is constant, modulation of the PWM drive signal can generally achieve this goal. In embodiments where the resistance of the evaporator element 109 varies significantly with temperature, the modulation must be performed with respect to power rather than PWM, and therefore, Fig.48c There are double labels on the vertical axis of . Embodiments of the control device 100 may be configured to modulate the Fig.48c The power delivered to the evaporator element 109 is reduced. During each subsequent inhalation event within a phase, gradually reducing the amount of inhalation medium dispensed onto the evaporator element 109 via the dispensing motor 112 provides an alternative way to reduce the amount of inhalation medium evaporated within a phase. The amount of inhalation medium dispensed during an inhalation may follow Fig.48c The same scheme as described in .

[0243] It is not only important to control the amount of active ingredient delivered in one phase, but also in multiple phases. For example, controlling the amount of active ingredient delivered in a day may be important to achieve the goal of abstinence. Fig.48dDemonstrates that the amount of active ingredient delivered in each stage can be varied and controlled to achieve daily goals. For smokers of combustible cigarettes, early morning is often a time when cravings for nicotine are high due to lack of smoking during sleep. In order to satisfy the user, a large amount of nicotine may need to be delivered. The amount of nicotine may be represented by a maximum stage level 4803. As the day progresses, a smaller amount of nicotine may be required within a stage to achieve satisfaction. For example, stages #2, #3a, and #4 may require less nicotine. A minimum stage level 4804 may also be implemented to ensure that any stage meets the minimum threshold for providing satisfaction. The amount of active ingredient to be delivered in each stage may be based on a fixed formula determined through user testing, or may be dynamically determined by an application that monitors the user's consumption pattern, the consumption pattern of other users of the network, and / or feedback from network users in order to suggest the optimal amount for each stage. It should also be understood that quitting behavior may be nonlinear; a user may make progress on a quitting plan, then regress or plateau over a period of time or at a certain moment. The application may take this into account when determining the amount of active ingredient to be delivered. Regression or plateauing is a phenomenon that can manifest itself on many time scales, including daily, weekly, or monthly. It can also be triggered by external conditions or events. For example, when an individual drinks alcohol at weekend dinner, his or her urge to smoke will typically increase. For example, the application can record this pattern and adjust stage #3b upward to provide the additional nicotine needed to achieve satisfaction at such times, while adjusting stage #2 downward to keep the user on track with their overall abstinence plan. If the application does not allow such adjustments, the urge to smoke may be too strong and the user may be tempted to smoke combustible cigarettes. Adjustments and compensation for regression or plateauing can be implemented on a variety of time scales, including but not limited to: daily, weekly, biweekly, and monthly. In addition, it should be understood that although nicotine is used to explain Figures 48a to 48d The present invention is an exemplary active ingredient of , but the present invention can be more widely applied to the withdrawal of other active ingredients.

[0244] Although the present disclosure has been described according to exemplary embodiments, those skilled in the art will recognize that the present disclosure can be practiced by modifying the spirit and scope of the appended claims. The examples given above are merely illustrative and are not intended to be an exhaustive list of all possible designs, embodiments, applications or modifications of the present disclosure.

Claims

1. An evaporative product, comprising: Evaporator drive circuit; one or more memories configured to store a percentage of at least one component in an inhaled medium, one or more compensation values ​​for the at least one component, and instructions; as well as control circuitry comprising a processor coupled to the one or more memories and configured to execute the instructions, the instructions being configured to cause the processor to: Dose targets for the receiving components; When compensation is to be performed, determining an appropriately compensated inhalation medium dose based on the associated compensation value of the component; as well as controlling the vaporizer drive circuit to dispense a compensating dose of the inhaled medium, The evaporative article is characterized in that the instructions are configured to cause the processor to: determining the amount by which the composition or potency of the inhaled medium has changed relative to a previous composition or potency; Determining whether to compensate the dose of the inhaled medium according to the change to ensure that the dose target is achieved; and When compensation is to be performed, the associated compensation value of the component is determined based on the change amount.

2. The evaporative article of claim 1, wherein the one or more compensation values ​​are compensation factors, and wherein compensation is performed by applying an appropriate one of the compensation factors to the inhalation medium dose.

3. The evaporative article of claim 2, wherein at least one of the one or more compensation values ​​is associated with a year of the inhalation medium, and wherein the one or more compensation values ​​include a list of year-dependent compensation factors for the at least one component.

4. The evaporative article of claim 2, wherein at least one of the one or more compensation values ​​is associated with at least one of exposure to high temperature, radiation, moisture, UV light, oxygen, and reaction with other components, and wherein the one or more compensation values ​​include a list of time-dependent compensation factors for the at least one component.

5. The evaporative article of claim 1, wherein the one or more compensation values ​​include a rate constant (k), and wherein compensation is performed by calculating a compensation factor based on the rate constant and applying the calculated compensation factor to the inhalation medium dose.

6. The evaporative article of claim 5, wherein the compensation factor is calculated using the following equation: Compensation factor = 1÷e -kt ; where e = base of the natural logarithm, k = rate constant, and t = time.

7. The vaporized article of claim 1, further comprising a dose selection input circuit, and wherein the dose target is received via the dose selection input circuit.

8. The evaporative article of claim 1, further comprising a communication interface circuit, and wherein the dose target is received via the communication interface circuit.

9. The vaporizing article of claim 1, wherein the at least one ingredient comprises at least one of CBD or nicotine.

10. The evaporative article of claim 1, wherein the one or more memories include a remote memory.

11. The evaporative article of claim 10, wherein the one or more compensation values ​​are stored in the remote memory.

12. The evaporative article of claim 11, wherein the one or more compensation values ​​include a rate constant (k), and wherein a compensation factor is calculated based on the rate constant, and wherein compensation is performed by the processor receiving the calculated compensation factor or compensation dose from a remote processor and applying the calculated compensation factor or compensation dose to the inhaled medium dose.

13. The evaporative article of claim 1, wherein determining to perform compensation comprises receiving an indication from a user to perform compensation.

14. The evaporative article of claim 1, wherein the processor is further configured to automatically determine whether to perform compensation.

15. The evaporative article of claim 14, wherein the processor is configured to automatically perform compensation whenever a dose target is received.

16. The evaporative article of claim 14, wherein the processor is further configured to automatically determine whether the uncompensated dose of inhaled medium will deliver the dose target, and automatically perform compensation when it is determined that the uncompensated dose of inhaled medium will not deliver the dose target.

17. The evaporative article of claim 1, wherein the percentage of at least one component in the inhalation medium is a mass percentage.

18. A method for compensating the dosage of an inhaled medium, comprising: storing in a memory a percentage of at least one component in the inhaled medium, one or more compensation values ​​for the at least one component; as well as Dose targets for the receiving components; When compensation is to be performed, determining an appropriately compensated inhalation medium dose based on the associated compensation value of the component; as well as determining a drive signal required to disperse a compensated amount of the inhaled medium based on the appropriately compensated inhaled medium amount, The method is characterized in that: determining the amount by which the composition or potency of the inhaled medium has changed relative to a previous composition or potency; Determining whether to compensate the dose of the inhaled medium according to the change to ensure that the dose target is achieved; as well as When compensation is to be performed, the associated compensation value of the component is determined based on the change amount.

19. The method of claim 18, wherein the one or more compensation values ​​are compensation factors, and wherein compensation is performed by applying an appropriate one of the compensation factors to the inhaled medium dose.

20. The method of claim 19, wherein at least one of the one or more compensation values ​​is associated with a year of the inhaled medium, and wherein the one or more compensation values ​​include a list of year-dependent compensation factors for the at least one component.

21. The method of claim 19, wherein at least one of the one or more compensation values ​​is associated with at least one of exposure to high temperature, radiation, moisture, UV light, oxygen, and reaction with other components, and wherein the one or more compensation values ​​include a list of time-dependent compensation factors for the at least one component.

22. The method of claim 18, wherein the one or more compensation values ​​include a rate constant (k), and wherein compensation is performed by calculating a compensation factor based on the rate constant and applying the calculated compensation factor to the inhaled medium dose.

23. The method of claim 22, wherein the compensation factor is calculated using the following equation: Compensation factor = 1÷e -kt ; where e = base of the natural logarithm, k = rate constant, and t = time.

24. The method of claim 18, wherein the dose target is received via a dose selection input circuit.

25. The method of claim 18, wherein the dose target is received via a communication interface circuit.

26. The method of claim 18, wherein the at least one ingredient comprises at least one of CBD or nicotine.

27. The method of claim 18, wherein the one or more compensation values ​​are stored in a remote memory.

28. A method as claimed in claim 27, wherein the one or more compensation values ​​include a rate constant (k), and wherein a compensation factor is calculated based on the rate constant, and wherein the method further comprises receiving the calculated compensation factor or compensation dose from a remote processor and applying the calculated compensation factor or compensation dose to the inhaled medium dose.

29. The evaporative article of claim 1, wherein determining to perform compensation comprises receiving an indication from a user to perform compensation.

30. The method of claim 18, further comprising automatically determining whether an uncompensated dose of the inhaled medium will deliver the dose target, and automatically performing compensation when it is determined that the uncompensated dose of the inhaled medium will not deliver the dose target.

Images